-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I6Nd5IJM6FrQItJBB7e/oiQk4hl7ZW3Wk/VgIKT7/TYksuSw/YKVloau026Kz99i
 H1RW3z/Eqc9C2mCiIo/Zug==

<SEC-DOCUMENT>0001047469-11-000032.txt : 20110106
<SEC-HEADER>0001047469-11-000032.hdr.sgml : 20110106
<ACCEPTANCE-DATETIME>20110106082649
ACCESSION NUMBER:		0001047469-11-000032
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20110106
DATE AS OF CHANGE:		20110106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-165899
		FILM NUMBER:		11512813

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2201537z424b5.htm
<DESCRIPTION>425B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg15101_table_of_contents">  Table of Contents</A> <BR>
<A HREF="#bg15102_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-165899  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Prospectus Supplement<BR>
(to Prospectus dated April&nbsp;22, 2010)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,000,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g148431.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="63">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a sales agreement with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. relating to shares of our common stock offered by this
prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, we may offer and sell up to 5,000,000 shares of our common stock, $0.001 par value per
share, from time to time through Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. acting as agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the NASDAQ Global Market under the symbol "CLDX." The last reported sale price of our common stock on the NASDAQ Global Market on January&nbsp;5, 2011 was
$4.18 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be "at-the-market" equity
offerings as defined in Rule&nbsp;415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through the NASDAQ Global Market, the existing trading market for
our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to
such prevailing market prices, and/or any other method permitted by law. Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. will act as sales agent on a best efforts basis. There is no arrangement for funds to be
received in any escrow, trust or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
Fitzgerald&nbsp;&amp;&nbsp;Co. will be entitled to compensation at a fixed commission rate up to 5.0% of the gross sales price per share sold. In connection with the sale of the
common stock on our behalf, Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. may be deemed to be an "underwriter" within the meaning of the Securities Act of 1933, as amended, and the compensation of Cantor
Fitzgerald&nbsp;&amp;&nbsp;Co. may be deemed to be underwriting commissions or discounts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Before buying shares of our common stock, you should carefully consider the risk factors described in "Risk Factors" beginning on
page&nbsp;S-6 of this prospectus supplement, beginning on page&nbsp;9 of the accompanying prospectus, and those contained in our incorporated documents, to read about factors you
should consider before buying our securities.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved of anyone's investment in these securities, or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1023782.jpg" ALT="GRAPHIC" WIDTH="171" HEIGHT="58">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>The date of this prospectus supplement is January&nbsp;6, 2011.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=364671,FOLIO='blank',FILE='DISK131:[11ZAB1.11ZAB15101]BE15101A.;8',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg15101_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="BG15101A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg15101_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG15101_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus Supplement</A></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bm15101_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About This Prospectus</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bm15101_about_this_prospectus"><FONT SIZE=2>S-1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bm15101_cautionary_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bm15101_cautionary_note_regarding_forward-looking_statements"><FONT SIZE=2>S-2</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca15101_prospectus_supplement_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Supplement Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca15101_prospectus_supplement_summary"><FONT SIZE=2>S-3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca15101_the_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Offering</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca15101_the_offering"><FONT SIZE=2>S-5</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da15101_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da15101_risk_factors"><FONT SIZE=2>S-6</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de15101_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de15101_use_of_proceeds"><FONT SIZE=2>S-20</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de15101_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de15101_dilution"><FONT SIZE=2>S-21</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#page_de15101_1_22"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#page_de15101_1_22"><FONT SIZE=2>S-22</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#page_de15101_1_23"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#page_de15101_1_23"><FONT SIZE=2>S-23</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#page_de15101_1_23"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#page_de15101_1_23"><FONT SIZE=2>S-23</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#page_de15101_1_23"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#page_de15101_1_23"><FONT SIZE=2>S-23</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de15101_incorporation_of_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Documents By Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de15101_incorporation_of_documents_by_reference"><FONT SIZE=2>S-24</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1><B><BR>&nbsp;</B></FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B><BR>
Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi15102_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi15102_prospectus_summary"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi15102_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi15102_special_note_regarding_forward-looking_statements"><FONT SIZE=2>7</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de15102_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de15102_risk_factors"><FONT SIZE=2>9</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of Earnings to Fixed Charges</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>22</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_use_of_proceeds"><FONT SIZE=2>22</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Securities We May Offer</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_descriptions_of_securities_we_may_offer"><FONT SIZE=2>22</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_description_of_common_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Common Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_description_of_common_stock"><FONT SIZE=2>23</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_description_of_preferred_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Preferred Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_description_of_preferred_stock"><FONT SIZE=2>24</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Warrants</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_description_of_warrants"><FONT SIZE=2>26</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg15102_description_of_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Depositary Shares</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg15102_description_of_depositary_shares"><FONT SIZE=2>28</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_description_of_units"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Units</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_description_of_units"><FONT SIZE=2>29</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_plan_of_distribution"><FONT SIZE=2>29</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Documents By Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_incorporation_of_certain_documents_by_reference"><FONT SIZE=2>31</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_legal_matters"><FONT SIZE=2>32</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_experts"><FONT SIZE=2>32</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di15102_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di15102_where_you_can_find_more_information"><FONT SIZE=2>33</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You should rely only on the information we have provided or incorporated by reference in this prospectus supplement or in the accompanying prospectus. We have not
authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus supplement or in the accompanying prospectus. This prospectus supplement
is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information contained in this
prospectus supplement and in the accompanying prospectus is accurate only as of their respective dates and that any information we have incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or any sale of securities.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=864185,FOLIO='S-i',FILE='DISK131:[11ZAB1.11ZAB15101]BG15101A.;8',USER='CDESORM',CD=';5-JAN-2011;17:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bm15101_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bm15101_about_this_prospectus"> </A>
<A NAME="toc_bm15101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document is in two parts. The first part is this prospectus supplement, which describes the terms of the offering and also adds to
and updates information contained in the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information. To the extent there is a conflict between the
information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus, on the other hand, you should rely on the information in this
prospectus supplement. It is also important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents we have
referred you to in the section entitled "Where You Can Find More Information" below in this prospectus supplement. The information incorporated by reference is considered part of this prospectus
supplement, and information we file later with the Securities and Exchange Commission, or SEC, may automatically update and supersede this information. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were
made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a
representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied
on as accurately representing the current state of our affairs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein. We have not authorized, and the
placement agents have not authorized, anyone to provide you with information that is different. The information contained in this prospectus supplement or the accompanying prospectus or incorporated
by reference herein or therein is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of
our common stock. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by
reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled "Where You
Can Find More Information" and "Incorporation of Documents by Reference" in this prospectus supplement and in the accompanying prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and
the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus
supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement
and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make
such an offer or solicitation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address of our principal executive office is Celldex Therapeutics,&nbsp;Inc., 119 Fourth Avenue, Needham, Massachusetts 02494, and our telephone number is
(781)&nbsp;433-0771. Our corporate website address is www.celldextherapeutics.com. The information contained on our website is not a part of, and should not be construed as being
incorporated by reference into, this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context otherwise requires, "Celldex," the "Company," "we," "us," "our" and similar names refer to Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=301095,FOLIO='S-1',FILE='DISK131:[11ZAB1.11ZAB15101]BM15101A.;2',USER='CDESORM',CD=';5-JAN-2011;17:40' -->
<A NAME="page_bm15101_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bm15101_cautionary_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_bm15101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement, the accompanying prospectus, and the documents we have filed with the SEC that are incorporated herein by
reference contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Words
such as "may," "should," "anticipate," "estimate," "expect," "projects," "intends," "plans," "believes" and words and terms of similar substance used in connection with any
discussion of future operating or financial performance, identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject
to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks
and uncertainties regarding our preclinical studies, our ability to conduct clinical trials of our product candidates and the results of such trials, as well as risks and uncertainties relating to
future capital needs, economic conditions, dependence on our collaborators, litigation, government regulation and third-party reimbursement, markets, products, competition, intellectual property,
services and prices, key employees and other factors. Please also see the discussion of risks and uncertainties under "Risk Factors" below, contained in the accompanying prospectus and otherwise
incorporated by reference herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this prospectus supplement, the accompanying
prospectus or in any document incorporated herein by reference might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the
respective dates of this prospectus supplement, the accompanying prospectus or the date of the document incorporated by reference in this prospectus or the accompanying prospectus. We expressly
disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=762721,FOLIO='S-2',FILE='DISK131:[11ZAB1.11ZAB15101]BM15101A.;2',USER='CDESORM',CD=';5-JAN-2011;17:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca15101_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca15101_prospectus_supplement_summary"> </A>
<A NAME="toc_ca15101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary is qualified in its entirety by, and should be read together with, the more detailed
information and financial statements and related notes thereto appearing elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. Before you decide to
invest in our common stock, you should read the entire prospectus supplement and the accompanying prospectus carefully, including the risk factors and the financial statements and related notes
included or incorporated by reference in this prospectus supplement and the accompanying prospectus.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Company Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company currently focusing on the development of CDX-110 (rindopepimut), our lead product
candidate, and two other promising product candidates, CDX-011, which is in clinical development, and CDX-1127, which is in pre-clinical research. We have several
other
product candidates in various stages of clinical and pre-clinical development which we expect to seek to out-license as opportunities arise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> CDX-110 (rindopepimut)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-110 is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor
receptor variant III, or EGFRvIII, in patients with Glioblastoma Multiforme, or GBM, the most common and aggressive form of brain cancer. EGFRvIII has also been observed in various other cancers such
as breast, ovarian, prostate, colorectal, and head&nbsp;&amp; neck cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
recently regained the rights to develop and commercialize CDX-110 from Pfizer Vaccines,&nbsp;LLC, or Pfizer. We had a License and Development Agreement with Pfizer under
which Pfizer was granted an exclusive worldwide license to CDX-110. Pfizer terminated that agreement effective November&nbsp;1, 2010. Under that agreement, Pfizer had made a
$40&nbsp;million up-front payment to us, and a $10&nbsp;million equity investment in Celldex, and had reimbursed development costs for a twenty-nine month period. Upon
receipt of the up-front payment from Pfizer, under our agreements with Duke University, or Duke, and Thomas Jefferson University, or TJU, we paid a cash sublicense fee of
$1.2&nbsp;million to Duke and issued to Duke 81,512 shares of our common stock valued at $1.2&nbsp;million, and paid a cash sublicense fee of $4.5&nbsp;million to TJU. We expect that we will
make additional payments to Duke and TJU in the event that CDX-110 is commercialized or partnered with another company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Society of Neuro-Oncology Annual Meeting held November&nbsp;18 through 21, 2010, we presented final data on the 5.5-month Progression Free Rate ("PFR") from all 65
patients enrolled in the ACT III study as well as an update on Overall Survival ("OS") data from this study. Final OS data from the ACT II study was also presented. These data provide additional
information that will allow us to better design the future clinical development of rindopepimut. We currently plan to initiate a Phase&nbsp;3 randomized study of CDX-110 in patients with
GBM by the second half of 2011. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> CDX-011 (glembatumumab vedotin)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September 2010, we initiated a 120 patient randomized Phase&nbsp;2b controlled study of CDX-011, our antibody drug
conjugate for the treatment of patients with glycoprotein NMB, or&nbsp;GPNMB, expressing advanced, refractory breast cancer. CDX-011 targets the protein&nbsp;GPNMB, which is over
expressed in a variety of cancers including breast cancer, melanoma and brain tumors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> CDX-1127  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a License Agreement with the University of Southampton, UK, to develop human antibodies to CD27, a potentially
important target for immunotherapy of various cancers. In preclinical models, antibodies to CD27 alone have been shown to mediate anti-tumor effects, and may be particularly effective in
combination with other immunotherapies. CD27 is a critical molecule in the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=623103,FOLIO='S-3',FILE='DISK131:[11ZAB1.11ZAB15101]CA15101A.;8',USER='CDESORM',CD=';5-JAN-2011;17:40' -->
<A NAME="page_ca15101_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>activation
pathway of lymphocytes. It acts downstream from CD40 and may provide a novel way to regulate the immune responses. In September 2010, we exercised an option under our Research and
Commercialization Agreement with Medarex, whereby we have a commercial license to the Medarex human antibody technology specifically for our CD27 antibody. Preclinical models with our human monoclonal
antibody to CD27 have demonstrated immune cell activation and anti-tumor responses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Other Clinical and Pre-Clinical Programs  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to regaining the right to develop CDX-110, we had several other programs in clinical and pre-clinical
development. As we focus on the development of CDX-110, CDX-011, and CDX-1127, we will seek opportunities to have third-party academic and governmental
collaborators fund these other programs or to out-license the development of these other programs to corporate partners. The status of these other programs is summarized in the table
below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="26%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="247pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="26%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Product Candidate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stage of Clinical Development </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Muscle-invasive bladder cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Randomized Phase&nbsp;2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cancer, autoimmune disease and transplant</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal and ovarian cancer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CDX-1189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Rotarix  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, we licensed our oral rotavirus strain to GlaxoSmithKline&nbsp;plc, or Glaxo, and Glaxo assumed responsibility for all
subsequent clinical trials and all other development activities. Glaxo gained approval for its rotavirus vaccine, Rotarix&reg;, in Mexico in 2004, which represented the first in a series of
worldwide approvals and commercial launches for the product leading up to the approval in Europe in 2006 and in the U.S. in 2008. We licensed-in our rotavirus strain in 1995 and owe a
license fee of 30% to Cincinnati Children's Hospital Medical Center, or CCH, on net royalties received from Glaxo. We are obligated to maintain a license with CCH with respect to the Glaxo agreement.
The term of the Glaxo agreement is through the expiration of the last of the relevant patents covered by the agreement, although Glaxo may terminate the agreement upon 90&nbsp;days prior written
notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund II,&nbsp;L.P., or PRF, purchased an interest in the milestone payments and net royalties that we receive
on the development and worldwide sales of Rotarix&reg;. We have received a total of $60&nbsp;million in milestone payments under the PRF agreement through September&nbsp;30, 2010. No
additional milestone payments are due from PRF under the agreement. Once PRF receives $147&nbsp;million on royalties on the sale of Rotarix&reg;, we will be able to retain approximately
92.5% of the royalties on worldwide sales of Rotarix&reg;. We do not anticipate this happening in the next two years, if at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. On March&nbsp;7, 2008, a wholly-owned subsidiary of Celldex (formerly named AVANT
Immunotherapeutics,&nbsp;Inc.) merged with and into what was then Celldex Therapeutics,&nbsp;Inc., a privately-held company. Through that merger we acquired the CDX-110
program. On October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex merged with and into CuraGen Corporation. As a result of that merger, we acquired the CDX-011 program. On
December&nbsp;31, 2009, CuraGen Corporate was merged with and into Celldex and the separate existence of CuraGen ceased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 119 Fourth Avenue, Needham, Massachusetts 02494 and our telephone number is (781)&nbsp;433-0771. Our corporate website is
www.celldextherapeutics.com. The information on our website is not incorporated by reference into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=656610,FOLIO='S-4',FILE='DISK131:[11ZAB1.11ZAB15101]CA15101A.;8',USER='CDESORM',CD=';5-JAN-2011;17:40' -->
<A NAME="page_ca15101_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca15101_the_offering"> </A>
<A NAME="toc_ca15101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


</FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Common stock we are offering pursuant to the prospectus supplement</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Up to 5,000,000 shares.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>Common stock to be outstanding after this offering (assuming all 5,000,000 shares are issued)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>37,054,238 shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Manner of offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>"At-the-market" offering that may be made from time to time through our agent, Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. See "Plan of Distribution" beginning on page&nbsp;S-22.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>We expect to use the net proceeds from this offering to fund clinical trials of our product candidates and for working capital and other general corporate purposes. See "Use of Proceeds" on
page&nbsp;S-20 of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>This investment involves a high degree of risk. You should read the description of risks set forth under "Risk Factors" beginning on page&nbsp;S-6 of this prospectus supplement or otherwise
incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>NASDAQ Global Market common stock symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>CLDX</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of common stock to be outstanding after this offering in the table above is based on 32,054,238 shares of common stock outstanding as of November&nbsp;10, 2010,
which does not include the following, all as of November&nbsp;10, 2010: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>4,002,234 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $6.95
per share;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>1,725,437 shares available for future issuance under our equity compensation plans; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>353,563 shares issuable upon the conversion of our outstanding 4% convertible notes, which may be converted into common
stock at any time, subject to certain limitations, on or before February&nbsp;15, 2011, at a conversion price of $35.36 per share, subject to adjustments in certain events. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=195725,FOLIO='S-5',FILE='DISK131:[11ZAB1.11ZAB15101]CA15101A.;8',USER='CDESORM',CD=';5-JAN-2011;17:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da15101_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da15101_risk_factors"> </A>
<A NAME="toc_da15101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>An investment in our securities involves a high degree of risk. You should carefully consider the risks
described under "Risk Factors" in the accompanying prospectus, our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009 and our Quarterly Report on
Form&nbsp;10-Q for the fiscal quarter ended September&nbsp;30, 2010, as updated by any other document that we subsequently file with the Securities and Exchange Commission and that is
incorporated by reference into this prospectus supplement, as well as the risks described below and all of the other information contained in this prospectus supplement and the accompanying
prospectus, and incorporated by reference into this prospectus supplement and the accompanying prospectus, including our financial statements and related notes, before investing in our securities. If
any of the possible events described in those sections actually occur, our business, business prospects, cash flow, results of operations or financial condition could be harmed. In this case, the
trading price of our common stock could decline, and you might lose all or part of your investment in our common stock.</I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a discussion of the risk factors that we believe are material to us at this time. These risks and uncertainties are not the only ones facing us and there may be
additional matters that we are unaware of or that we currently consider immaterial. All of these could adversely affect our business, results of operations, financial condition and cash flows. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to this Offering  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We currently have no product revenue and will need to raise capital to operate our business in addition to funds we receive in this offering.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have generated no product revenue. Until, and unless, we complete clinical trials and further development, and receive
approval from the Food and Drug Administration, or FDA, and other regulatory authorities for our product candidates, we cannot sell our drugs and will not have product revenue. Therefore, for the
foreseeable future, we will have to fund all of our operations and development expenditures from cash on hand, equity or debt financings, licensing fees and grants. While the funds we receive in this
offering will help fund our operations, additional financing will also be required. If we do not succeed in raising additional funds on acceptable terms, we might not be able to complete planned
preclinical and clinical trials or obtain approval of any product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development, reduce
or forego sales and marketing efforts, forego attractive business opportunities or curtail operations. Any additional sources of financing could involve the issuance of our equity securities, which
would have a dilutive effect on our stockholders. No assurance can be given that additional financing will be available to us when needed on acceptable terms, or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will
have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the
net proceeds for corporate purposes that may not improve our financial condition or market value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>You will experience immediate and substantial dilution in the book value per share of the common stock you purchase.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because the price per share of our common stock being offered may be higher than the book value per share of our common stock, you may
suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. See the section entitled "Dilution" below for a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=187982,FOLIO='S-6',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_da15101_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>more
detailed discussion of the dilution you will incur if you purchase common stock in this offering. In addition, we have a significant number of options, convertible notes and restricted stock
outstanding. If the holders of these securities exercise or convert them or become vested in them, as applicable, you may incur further dilution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the
market price of our common stock.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock or other equity-related securities in the public markets could depress the
market price of our common stock and impair our ability to raise capital through the sale of additional equity securities, including sales hereunder through Cantor. We cannot predict the effect that
future sales of our common stock or other equity-related securities would have on the market price of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to our Capital Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Our history of losses and uncertainty of future profitability make our common stock a highly speculative investment.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have had no commercial revenues to date from sales of our human therapeutic or vaccine products and cannot predict when we will. We
had an accumulated deficit of
$183&nbsp;million as of September&nbsp;30, 2010. We expect to spend substantial funds to continue the research and development testing of our products that we have in the preclinical and clinical
testing stages of development that have not been partnered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities.
These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the regulatory approval process. As a
result, we may continue to lose money for several years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
common stock, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>If we cannot sell capital stock to raise necessary funds, we may be forced to limit our research, development and testing programs.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will need to raise more capital from investors to advance our clinical and preclinical products and to fund our operations until we
receive final FDA approval and our products begin to generate revenues for us. However, based on our history of losses and the on-going uncertainty of the U.S. capital markets, we may have
difficulty raising sufficient capital on terms that are acceptable to us, or at all. As of September&nbsp;30, 2010, we had cash, cash equivalents and marketable securities of $57.7&nbsp;million,
which, at that time, we believed would support expected operations for more than 12&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continue to seek partnerships with pharmaceutical and biotech companies and with other organizations to support the clinical development of our programs, in addition to funded
research grants. This kind of funding is at the discretion of other organizations and companies which have limited funds and many companies compete with us for those funds. As a result, we may not
receive any research grants or funds from collaborators. If we are unable to raise the necessary funds, we may have to delay or discontinue the clinical development of programs, license out programs
earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or evaluate a sale of all or part of our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=756585,FOLIO='S-7',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_da15101_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
we begin generating revenue, we may seek funding through the sale of equity, or securities convertible into equity, and further dilution to the then existing stockholders may
result. If we raise additional capital through the incurrence of debt, our business may be affected by the amount of leverage it incurs, and its borrowings may subject it to restrictive covenants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Our share price has been and could remain volatile.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January
2010 through December&nbsp;2010, the market price of our common stock has fluctuated from a high of $9.49 per share in the second quarter of 2010, to a low of $2.91 per share in the third quarter of
2010. Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price
of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a
short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has
experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and
may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in
substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Our ability to use our net operating loss carryforwards will be subject to limitation and, under certain circumstances, may be eliminated.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization of our net operating loss, or NOL, and research and development credit carryforwards may be subject to substantial annual
limitation due to ownership change limitations that have occurred previously or that could occur in the future provided by Section&nbsp;382 of the Internal Revenue Code of 1986, or
Section&nbsp;382, as well as similar state provisions. In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain shareholders
or public groups in the stock of a corporation by more than 50&nbsp;percentage points over a three-year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2007, June 2009 and in December 2009, Celldex Research experienced a change in ownership as defined by Section&nbsp;382 of the Internal Revenue Code. Celldex Research, since
its formation, had raised capital through the issuance of capital stock on several occasions which, combined with shareholders' subsequent disposition of those shares, has resulted in three changes of
control, as defined by Section&nbsp;382. As a result of the ownership change in October 2007, utilization of its Federal NOLs is subject to an annual limitation. Any unused annual limitation may be
carried over
to later years, and the amount of the limitation may, under certain circumstances, be subject to adjustment if the fair value of the our net assets are determined to be below or in excess of the tax
basis of such assets at the time of the ownership change, and such unrealized loss or gain is recognized during the five-year period after the ownership change. Subsequent ownership
changes, as defined in Section&nbsp;382, could further limit the amount of net operating loss carryforwards and research and development credits that can be utilized annually to offset future
taxable income. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not undertaken a study to assess whether an ownership change or multiple ownership changes has occurred for Celldex Therapeutics, CuraGen, Celldex Research on the state level, or
research and development credits. If there has been an ownership change at any time since its formation, utilization of NOL or tax credit carryforwards would be subject to an annual limitation under
Section&nbsp;382. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=598697,FOLIO='S-8',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_da15101_1_9"> </A>


<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to our Business  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Pfizer's termination of its global development and commercialization agreement with us may cause uncertainty surrounding, as well as delays in and
increased costs for, the development of our lead clinical development program, which could adversely affect the value of our common stock, our cash position and results of operations.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had licensed our lead clinical development program, Rindopepimut, a therapeutic cancer vaccine candidate sometimes referred to as
CDX-110, to Pfizer pursuant to a License and Development Agreement dated April&nbsp;16, 2008, or the Pfizer Agreement, under which Pfizer was granted an exclusive worldwide license to
Rindopepimut and Pfizer would have funded all development costs for the program and would have commercialized the product. On September&nbsp;1, 2010, Pfizer provided a sixty day written notice to
terminate the Pfizer Agreement. Pfizer is in the process of transitioning back to us all current as well as planned activities related to the development of Rindopepimut. In November 2010, all rights
to the Rindopepimut program were returned to us. We are currently evaluating our options with respect to Rindopepimut, which may include licensing all or specific portions of the rights to the
Rindopepimut program to another third party collaborator or retaining the rights and funding the development of the Rindopepimut program ourselves. If we retain the rights to the Rindopepimut program
and are fully responsible for its development and commercialization, we may face delays, difficulties or unanticipated costs in completing the development and commercialization of the product and will
need substantial additional
financing. If we elect to enter into an agreement with a new third party collaborator for the licensing, development and commercialization of the product, the process of identifying a new collaborator
and negotiating a new collaboration agreement may cause delays and increased costs. In addition, we may not be able to enter into a new collaboration agreement on terms as favorable as the terms in
the Pfizer Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product
development.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these third parties fails to perform as we expect or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We depend greatly on third party collaborators to license, develop and commercialize some of our products, and they may not meet our expectations.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreements with third party collaborators for the licensing, development and ultimate commercialization of some of our
products. Some of those agreements give substantial responsibility over the products to the collaborator. Some collaborators may be unable or unwilling to devote sufficient resources to develop our
products as their agreements require. They often face business risks similar to ours, and this could interfere with their efforts. Also, collaborators may choose to devote their resources to products
that compete with ours. If a collaborator does not successfully develop any one of our products, we will need to find another collaborator to do so. The success of our search for a new collaborator
will depend on our legal right to do so at the time and whether the product remains commercially viable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
success of our products depends in great part upon our and our collaborators' success in promoting them as superior to other treatment alternatives. We believe that our products can
be proven to offer disease prevention and treatment with notable advantages over drugs in terms of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=152563,FOLIO='S-9',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_da15101_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>patient
compliance and effectiveness. However, there can be no assurance that we will be able to prove these advantages or that the advantages will be sufficient to support the successful
commercialization of our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We may face delays, difficulties or unanticipated costs in establishing sales, distribution and manufacturing capabilities for our commercially ready
products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have chosen to retain, rather than license, all rights to some of our lead products, such as CDX-011 and our
APC Targeting Technology programs. We also may chose to retain, rather than license to another third party, all rights to the Rindopepimut product. If we proceed with this strategy, we will have full
responsibility for commercialization of these products if and when they are approved for sale. We currently lack the marketing, sales and distribution capabilities that we will need to carry out this
strategy. To market any of our products directly, we must develop a substantial marketing and sales force with technical expertise and a supporting distribution capability. We have little expertise in
this area, and we may not succeed. We may find it necessary to enter into strategic partnerships on uncertain but potentially unfavorable terms to sell, market and distribute our products when they
are approved for sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our products are difficult to manufacture, especially in large quantities, and we have not yet developed commercial scale manufacturing processes for any of our products. We do
not currently plan to develop internal manufacturing capabilities to produce any of our products at commercial scale if they are approved for sale. To the extent that we choose to market and
distribute these products ourselves, this strategy will make us dependent on other companies to produce our products in adequate quantities, in compliance with regulatory requirements, and at a
competitive cost. We may not find third parties capable of meeting those manufacturing needs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Our products and product candidates are subject to extensive regulatory scrutiny.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our products and product candidates are at various stages of development and commercialization and our activities, products and
product candidates are significantly regulated by a number of governmental entities, including the FDA in the United States and by comparable authorities in other countries. These entities regulate,
among other things, the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of our products
and product candidates. We or our partners must obtain regulatory approval for a product candidate in all of these areas before we can commercialize the product candidate. Product development within
this regulatory framework takes a number of years and involves the expenditure of substantial resources. This process typically requires extensive preclinical and clinical testing, which may take
longer or cost more than we anticipate, and may prove unsuccessful due to numerous factors. Many product candidates that initially appear promising ultimately do not reach the market because they are
found to be unsafe or ineffective when tested. Companies in the pharmaceutical, biotechnology and vaccines industries have suffered significant setbacks in advanced clinical trials, even after
obtaining promising results in earlier trials. Our inability to commercialize a product or product candidate would impair our ability to earn future revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>If our products do not pass required tests for safety and effectiveness, we will not be able to derive commercial revenue from them.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to succeed, we will need to derive commercial revenue from the products we have under development. The FDA has not approved
our CDX-110 or CDX-011 product candidates or any of our other lead products for sale to date. Products in our vaccine programs are in various stages of preclinical and clinical
testing. Preclinical tests are performed at an early stage of a product's development and provide information about a product's safety and effectiveness on laboratory animals. Preclinical tests can
last years. If a product passes its preclinical tests satisfactorily, and we determine </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=528306,FOLIO='S-10',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_da15101_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>that
further development is warranted, we would file an IND application for the product with the FDA, and if the FDA gives its approval we would begin Phase&nbsp;1 clinical tests. Phase&nbsp;1
testing generally lasts between 6 and 24&nbsp;months. If Phase&nbsp;1 test results are satisfactory and the FDA gives its approval, we can begin Phase&nbsp;2 clinical tests. Phase&nbsp;2
testing generally lasts between 6 and 36&nbsp;months. If Phase&nbsp;2 test results are satisfactory and the FDA gives its approval, we can begin Phase&nbsp;3 pivotal studies. Phase&nbsp;3
studies generally last between 12 and 48&nbsp;months. Once clinical testing is completed and a new drug application is filed with the FDA, it may take more than a year to receive FDA approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases we must show that a pharmaceutical product is both safe and effective before the FDA, or drug approval agencies of other countries where we intend to sell the product, will
approve it for sale. Our research and testing programs must comply with drug approval requirements both in the United States and in other countries, since we are developing our lead products with
companies, including Glaxo, which intend to or could later decide to commercialize them both in the U.S. and abroad. A product may fail for safety or effectiveness at any stage of the testing process.
A major risk we face is the possibility that none of our products under development will come through the testing process to final approval for sale, with the result that we cannot derive any
commercial revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Product testing is critical to the success of our products but subject to delay or cancellation if we have difficulty enrolling patients.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our portfolio of potential products moves from preclinical testing to clinical testing, and then through progressively larger and
more complex clinical trials, we will need to enroll an increasing number of patients with the appropriate characteristics. At times we have experienced difficulty enrolling patients and we may
experience more difficulty as the scale of our clinical testing program increases. The factors that affect our ability to enroll patients are largely uncontrollable and include principally the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the nature of the clinical test;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the size of the patient population;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>patients' willingness to receive a placebo or less effective treatment on the control arm of a clinical study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the distance between patients and clinical test sites; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the eligibility criteria for the trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot enroll patients as needed, our costs may increase or it could force us to delay or terminate testing for a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn future revenues.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that none of the products or product candidates that we develop will obtain the regulatory approvals necessary for us to
begin commercializing them. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the nature of
the product candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory
approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular product candidate, including but not limited
to loss of patent term during the approval period. Furthermore, if we, or our partners, do not reach the market with our products before our competitors offer products for the same or similar uses, or
if we, or our partners, are not effective in marketing our products, our revenues from product sales, if any, will be reduced. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=13,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=693372,FOLIO='S-11',FILE='DISK131:[11ZAB1.11ZAB15101]DA15101A.;6',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc15101_1_12"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT> <FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large
pharmaceutical companies, firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research
institutions. These competitors include Alexion, Anadys, Antigenics, Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent, Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck,
NeoPharm, Northwest Biotherapeutics, Novavax, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Vical. Most of our competitors have substantially greater resources, more extensive experience in
conducting preclinical studies and clinical testing and obtaining regulatory approvals for their products, greater operating experience, greater research and development and marketing capabilities and
greater production capabilities than those of ours. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products, especially if we
experience any delay in obtaining required regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Failure to comply with applicable regulatory requirements would adversely impact our operations.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even after receiving regulatory approval, our products would be subject to extensive regulatory requirements, and our failure to comply
with applicable regulatory requirements will adversely impact our operations. In the United States, the FDA requires that the manufacturing
facility that produces a product meet specified standards, undergo an inspection and obtain an establishment license prior to commercial marketing. Subsequent discovery of previously unknown problems
with a product or its manufacturing process may result in restrictions on the product or the manufacturer, including withdrawal of the product from the market. Failure to comply with the applicable
regulatory requirements can result in fines, suspensions of regulatory approvals, product recalls, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We depend greatly on the intellectual capabilities and experience of our key executives and scientists and the loss of any of them could affect our
ability to develop our products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of Anthony S. Marucci, our President and Chief Executive Officer, or other key members of our staff, including Avery W.
Catlin, our Chief Financial Officer, Dr.&nbsp;Thomas Davis, our Chief Medical Officer, or Dr.&nbsp;Tibor Keler, our Chief Scientific Officer, could harm us. We entered into employment agreements
with Messrs.&nbsp;Marucci, Catlin, Davis and Keler. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability
to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial and marketing personnel, particularly as
we expand our activities in clinical trials, the regulatory approval process and sales and manufacturing. We routinely enter into consulting agreements with our scientific and clinical collaborators
and advisors, opinion leaders and heads of academic departments in the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who recruit patients
into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for this type of personnel from other companies,
research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>We rely on contract manufacturers. Should the cost, delivery and quality of clinical and commercial grade materials supplied by contract
manufacturers vary to our disadvantage, our business operations could suffer significant harm.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have small-lot manufacturing capability at our Fall River facility, we rely on sourcing from third-party
manufacturers for suitable quantities of some of our clinical and commercial grade materials essential to preclinical and clinical studies currently underway and to planned clinical trials in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=195209,FOLIO='S-12',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>addition
to those currently being conducted by third parties or us. The inability to have suitable quality and quantities of these essential materials produced in a timely manner would result in
significant delays in the clinical development and commercialization of products, which could adversely affect our business, financial condition and results of operations. We also rely on
collaborators and contract
manufacturers to manufacture proposed products in both clinical and commercial quantities in the future. Our leading vaccine candidates require specialized manufacturing capabilities and processes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may face difficulty in securing commitments from U.S. and foreign contract manufacturers as these manufacturers could be unwilling or unable to accommodate our needs. Relying on
foreign manufacturers involves peculiar and increased risks, including the risk relating to the difficulty foreign manufacturers may face in complying with the FDA's Good Manufacturing Practices, or
GMP, as a result of language barriers, lack of familiarity with GMP or the FDA regulatory process or other causes, economic or political instability in or affecting the home countries of our foreign
manufacturers, shipping delays, potential changes in foreign regulatory laws governing the sales of our product supplies, fluctuations in foreign currency exchange rates and the imposition or
application of trade restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurances that we will be able to enter into long-term arrangements with third party manufacturers on acceptable terms, or at all. Further, contract
manufacturers must also be able to meet our timetable and requirements, and must operate in compliance with GMP; failure to do so could result in, among other things, the disruption of product
supplies. As noted above, non-U.S. contract manufacturers may face special challenges in complying with the FDA's GMP requirements, and although we are not currently dependent on
non-U.S. collaborators or contract manufacturers, we may choose or be required to rely on non-U.S. sources in the future as we seek to develop stable supplies of increasing
quantities of materials for ongoing clinical trials of larger scale. Our dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to
develop and deliver products on a timely and competitive basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third-parties who we currently rely on for sourcing of suitable quantities of some of our clinical and commercial grade materials include: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pfizer, on a transitional basis, Bayer, and Genzyme for the CDX-110 drug product;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dalton for Hiltonol which is an integral part of several of our drug products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>3M for Resiquimod which is an integral part of several of our drug products; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Piramal for the CDX-011 drug product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or our third-party manufacturers are unable to produce drug material in suitable quantities of appropriate quality, in a timely manner, and at a feasible cost, our clinical tests
will face delays. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product
development.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. If any of these third parties fails to perform as we expect
or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=995565,FOLIO='S-13',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2><B>Certain factors could negatively affect the demand for and sales and profitability of Rotarix&reg;, which would have a material adverse
affect on our revenues.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Both the demand and ultimately the profitability of Rotarix&reg; are components to our success. We have licensed a rotavirus
strain to Glaxo for the purposes of Glaxo developing and commercializing their Rotarix&reg; vaccine worldwide. Glaxo gained approval for Rotarix&reg; in Mexico in July 2004, in the
European Union in February 2006 and in the United States in April 2008. In May 2005, we entered into an agreement whereby an affiliate of PRF purchased an interest in the net royalties we will receive
on worldwide sales of Rotarix&reg;. In addition, we retain upside participation in the worldwide net royalties from Rotarix&reg; once, and if, PRF receives an agreed upon return on
capital invested (2.45 times PRF's aggregate cash payments to us of $60&nbsp;million). The following are potential factors, among others, that may negatively affect the demand for
Rotarix&reg;: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Competitors in the pharmaceuticals, biotechnology and vaccines market have greater financial and management resources, and
significantly more experience in bringing products to market, and may develop, manufacture and market products that are more effective or less expensive than Rotarix&reg;; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Rotarix&reg; could be replaced by a novel product and may become obsolete;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Glaxo may be unable to prevent third parties from infringing upon their proprietary rights related to
Rotarix&reg;;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Users may not accept such a recently approved product without years of proven history; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We are dependent on Glaxo for the manufacturing, testing, acquisition of regulatory approvals, marketing, distribution and
commercialization of Rotarix&reg;. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on the sales of Rotarix&reg; and our results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Other factors could affect the demand for and sales and profitability of Rotarix&reg; and any other of our current or future products.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, other factors that could affect the demand for and sales and profitability of our products include, but are not limited
to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The timing of regulatory approval, if any, of competitive products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our, Glaxo's, or any other of our partners' pricing decisions, as applicable, including a decision to increase or decrease
the price of a product, and the pricing decisions of our competitors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Government and third-party payer reimbursement and coverage decisions that affect the utilization of our products and
competing products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Negative safety or efficacy data from new clinical studies conducted either in the U.S. or internationally by any party
could cause the sales of our products to decrease or a product to be recalled;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The degree of patent protection afforded our products by patents granted to or licensed by us and by the outcome of
litigation involving our or any of our licensor's patents;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The outcome of litigation involving patents of other companies concerning our products or processes related to production
and formulation of those products or uses of those products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The increasing use and development of alternate therapies;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The rate of market penetration by competing products; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=16,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1020855,FOLIO='S-14',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The termination of, or change in, existing arrangements with our partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on Glaxo's sales of Rotarix&reg; and on any other of our current or future products and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We may be unable to manage multiple late stage clinical trials for a variety of product candidates simultaneously.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue
developing all of our current products. The management of late stage clinical trials is more complex and time consuming than early stage trials. Typically early stage trials involve several hundred
patients in no more than 10-30 clinical sites. Late stage (Phase&nbsp;3) trials may involve up to several thousand patients in up to several hundred clinical sites and may require
facilities in several countries. Therefore, the project management required to supervise and control such an extensive program is substantially larger than early stage programs. As the need for these
resources is not known until some months before the trials begin it is necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this
team to be recruited quickly the sponsor is faced with a decision to delay the program or to initiate it with inadequate management resources. This may result in recruitment of inappropriate patients,
inadequate monitoring of clinical investigators and inappropriate handling of data or data analysis. Consequently it is possible that conclusions of efficacy or safety may not be acceptable to permit
filing of a BLA or NDA for any one of the above reasons or a combination of several. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We face the risk of product liability claims, which could exceed our insurance coverage, and produce recalls, each of which could deplete our cash
resources.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a participant in the pharmaceutical, biotechnology and vaccines industries, we are exposed to the risk of product liability claims
alleging that use of our products or product candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our products or
product candidates and may be made directly by patients involved in clinical trials of our products, by consumers or healthcare providers or by individuals, organizations or companies selling our
products. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
covering product liability claims becomes increasingly expensive as a product candidate moves through the development pipeline to commercialization. Under our license
agreements, we are required to maintain clinical trial liability insurance coverage up to $14&nbsp;million. However, there can be no assurance that such insurance coverage is or will continue to be
adequate or available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be
able to secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability for damages resulting from a product liability claim could
exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material adverse effect on our business, financial condition and results of
operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business and inhibit or prevent commercialization of other products and
product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If we cannot maintain acceptable amounts
of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material
adverse impact on our operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=17,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=302558,FOLIO='S-15',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2><B>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements will typically restrict the ability of our
collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are
notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are typically
controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets
under the terms of research and development partnership or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach
of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of
publication. A competitor's discovery of our trade secrets would impair our competitive position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We may not be able to successfully integrate newly-acquired technology with our existing technology or to modify our technologies to create new
vaccines.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our acquisition of technology assets from entities such as 3M Company and Amgen, we have acquired access to
Resiquimod&#153; (a TLR&nbsp;7/8 agonist) and Flt3L, which may improve the immunogenicity of our vaccines. If we are able to integrate these licensed assets with our vaccine technologies, we
believe these assets will give our vaccines a competitive advantage. However, if we are unable to successfully integrate licensed assets, or other technologies which we have acquired or may acquire in
the future, with our existing technologies and potential products currently under development, we may be unable to realize any benefit from our acquisition of these assets, or other technologies which
we have acquired or may acquire in the future and may face the loss of our investment of financial resources and time in the integration process. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our vaccine technology portfolio may offer opportunities to develop vaccines that treat a variety of oncology, inflammatory and infectious diseases by stimulating a
patient's immune system against those disease organisms. If our vaccine technology portfolio cannot be used to create effective vaccines against a variety of disease organisms, we may lose all or
portions of our investment in development efforts for new vaccine candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>We license technology from other companies to develop products, and those companies could influence research and development or restrict our use of
it.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Companies that license technologies to us that we use in our research and development programs may require us to achieve milestones or
devote minimum amounts of resources to develop products using those technologies. They may also require us to make significant royalty and milestone payments, including a percentage of any
sublicensing income, as well as payments to reimburse them for patent costs. The number and variety of our research and development programs require us to establish priorities and to allocate
available resources among competing programs. From time to time we may choose to slow down or cease our efforts on particular products. If in doing so we fail to fully perform our obligations under a
license, the licensor can terminate the licenses or permit our competitors to use the technology. Moreover, we may lose our right to market and sell any products based on the licensed technology. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=18,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=786852,FOLIO='S-16',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2><B>We have many competitors in our field and they may develop technologies that make ours obsolete.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology, pharmaceuticals and therapeutics are rapidly evolving fields in which scientific and technological developments are
expected to continue at a rapid pace. We have many competitors in the U.S. and abroad. These competitors include Alexion, Anadys, Antigenics, Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent,
Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck, NeoPharm, Northwest Biotherapeutics, Novavax, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Vical. Our success depends
upon our ability to develop and maintain a competitive position in the product categories and technologies on which we focus. Many of our competitors have greater capabilities, experience and
financial resources than we do. Competition is intense and is expected to increase as new products enter the market and new technologies become available. Our competitors
may: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>develop technologies and products that are more effective than ours, making ours obsolete or otherwise noncompetitive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain regulatory approval for products more rapidly or effectively than us; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain patent protection or other intellectual property rights that would block our ability to develop competitive
products. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B>We rely on patents, patent applications and other intellectual property protections to protect our technology and trade secrets; which are expensive
and may not provide sufficient protection.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to obtain and maintain patent protection for technologies that we use. Biotechnology patents
involve complex legal, scientific and factual questions and are highly uncertain. To date, there is no consistent policy regarding the breadth of claims allowed in biotechnology patents, particularly
in regard to patents for technologies for human uses like those we use in our business. We cannot predict whether the patents we seek will issue. If they do issue, a competitor may challenge them and
limit their scope. Moreover, our patents may not afford effective protection against competitors with similar technology. A successful challenge to any one of our patents could result in a third
party's ability to use the technology covered by the patent. We also face the risk that others will infringe, avoid or circumvent our patents. Technology that we
license from others is subject to similar risks and this could harm our ability to use that technology. If we, or a company that licenses technology to us, were not the first creator of an invention
that we use, our use of the underlying product or technology will face restrictions, including elimination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we must defend against suits brought against us or prosecute suits against others involving intellectual property rights, we will incur substantial costs. In addition to any potential
liability for significant monetary damages, a decision against us may require us to obtain licenses to patents or other intellectual property rights of others on potentially unfavorable terms. If
those licenses from third parties are necessary but we cannot acquire them, we would attempt to design around the relevant technology, which would cause higher development costs and delays, and may
ultimately prove impracticable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Our business requires us to use hazardous materials, which increases our exposure to dangerous and costly accidents.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development activities involve the use of hazardous chemicals, biological materials and radioactive compounds.
Although we believe that our safety procedures for handling and disposing of hazardous materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate
the risk of accidental contamination or injury from these materials. In the event of an accident, an injured party will likely sue us for any resulting damages with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=19,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=566628,FOLIO='S-17',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>potentially
significant liability. The ongoing cost of complying with environmental laws and regulations is significant and may increase in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Health care reform and restrictions on reimbursement may limit our returns on potential products.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our strategy ultimately depends on the commercial success of our products, we assume, among other things, that end users of our
products will be able to pay for them. In the United States and other countries, in most cases, the volume of sales of products like those we are developing depends on the availability of
reimbursement from third-party payors, including national health care agencies, private health insurance plans and health maintenance organizations. Third-party payors increasingly challenge the
prices charged for medical products and services. Accordingly, if we succeed in bringing products to market, and reimbursement is not available or is insufficient, we could be prevented from
successfully commercializing our potential products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
health care industry in the United States and in Europe is undergoing fundamental changes as a result of political, economic and regulatory influences. Reforms proposed from time to
time include mandated basic health care benefits, controls on health care spending, the establishment of governmental controls over the cost of therapies, creation of large medical services and
products purchasing groups and fundamental changes to the health care delivery system. We anticipate ongoing review and assessment of health care delivery systems and methods of payment in the United
States and other countries. We cannot predict whether any particular reform initiatives will result or, if adopted, what their impact on us will be. However, we expect that adoption of any reform
proposed will impair our ability to market products at acceptable prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Changes in laws affecting the health care industry could adversely affect our business.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., there have been numerous proposals considered at the federal and state levels for comprehensive reforms of health care and
its cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. Congress has considered legislation to reform the U.S.
health care system by expanding health insurance coverage, reducing health care costs and making other changes. While health care reform may increase the number of patients who have insurance coverage
for our products, it may also include cost containment measures that adversely affect reimbursement for our products. Congress has also considered legislation to change the Medicare reimbursement
system for outpatient drugs, increase the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs and facilitate the importation of lower-cost
prescription drugs that are marketed outside the U.S. Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting
manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations
continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed
care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on
prices and reimbursement for our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our collaborators and partners operate in a highly regulated industry. As a result, governmental actions may adversely affect our business, operations or financial condition,
including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to
health care availability, method of delivery and payment for health care products and services;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and
result in lost market opportunity; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=20,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1038189,FOLIO='S-18',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<A NAME="page_dc15101_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on
product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of
approved products, or otherwise adversely affect the market for our products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations and judicial decisions affecting pricing or marketing practices; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the tax laws relating to our operations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment in the U.S. of health care reform, possible legislation which could ease the entry of competing follow-on biologics in the marketplace, new legislation or
implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of
previously enacted and possible future changes in laws that could adversely affect our business. In addition, the Food and Drug Administration Amendments Act of 2007 included new authorization for the
FDA to require post-market safety monitoring, along with an expanded clinical trials registry and clinical trials results database, and expanded authority for the FDA to impose civil
monetary penalties on companies that fail to meet certain commitments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>If physicians, patients and third-party payors do not accept any future drugs that we may develop, we may be unable to generate significant revenue,
if any.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if our drug candidates as well as any drug candidates that we may develop or acquire in the future obtain regulatory approval,
they may not gain market acceptance among physicians, patients and health care payors. Physicians may elect not to recommend these drugs for a variety of reasons including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>timing of market introduction of competitive drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lower demonstrated clinical safety and efficacy compared to other drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of cost-effectiveness;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of availability of reimbursement from third-party payors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>convenience and ease of administration;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>prevalence and severity of adverse side effects;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>other potential advantages of alternative treatment methods; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ineffective marketing and distribution support. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our approved drugs fail to achieve market acceptance, we would not be able to generate sufficient revenue from product sales to maintain or grow our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=21,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=297121,FOLIO='S-19',FILE='DISK131:[11ZAB1.11ZAB15101]DC15101A.;5',USER='HYUNG',CD=';4-JAN-2011;22:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de15101_1_20"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_use_of_proceeds"> </A>
<A NAME="toc_de15101_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to use the net proceeds from the sale of the shares of our common stock offered pursuant to this prospectus supplement to
fund clinical trials of our product candidates and for working capital and other general corporate purposes. At this time, we have not determined the approximate amount of net proceeds that will be
allocated to each of the uses of proceeds stated above. In addition, we may use the net proceeds from this offering for a variety of other corporate uses, including in-licenses or
acquisitions of complementary products, technologies or companies, although we currently have no commitments or agreements for any such transactions. Our management will retain broad discretion as to
the allocation of the net proceeds from this offering. Pending application of the net proceeds as described above, we intend to invest the net proceeds generally in short-term, investment
grade, interest bearing securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=526907,FOLIO='S-20',FILE='DISK131:[11ZAB1.11ZAB15101]DE15101A.;5',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_de15101_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_dilution"> </A>
<A NAME="toc_de15101_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net tangible book value on September&nbsp;30, 2010 was approximately $15.7&nbsp;million, or $0.49 per share. "Net tangible book
value" is total assets minus the sum of liabilities and intangible assets. "Net tangible book value per share" is net tangible book value divided by the total number of shares outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to the sale of all 5,000,000 shares of common stock being offered in this offering (assuming all 5,000,000 shares are issued at once) at an assumed offering price of
$4.18 per share, which was the closing price of our common stock as reported on the NASDAQ Global Market on January&nbsp;5, 2011, and after deducting estimated offering commissions and expenses
payable by us, our net tangible book value as of September&nbsp;30, 2010 would have been approximately $35.6&nbsp;million, or $0.96 per share of common stock. This represents an immediate increase
in net tangible book value of $0.47 per share to our existing stockholders and an immediate dilution in net tangible book value of $3.22 per share to investors participating in this offering. The
following table illustrates this dilution per share to investors participating in this offering: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:60%;margin-left:20%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net tangible book value per share as of September&nbsp;30, 2010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to new investors in offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share after giving effect to the offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.96</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase our common stock or outstanding warrants
to purchase shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above discussion and table are based on 32,051,938 shares of our common stock issued and outstanding as of November&nbsp;10, 2010, which does not include the following, all as of
November&nbsp;10, 2010: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>4,002,234 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $6.95
per share;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>1,725,437 shares available for future issuance under our equity compensation plans; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>353,563 shares issuable upon the conversion of our outstanding 4% convertible notes, which may be converted into common
stock at any time, subject to certain limitations, on or before February&nbsp;15, 2011, at a conversion price of $35.36 per share, subject to adjustments in certain events. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that any of these outstanding options or warrants are exercised, there will be further dilution to new investors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=111933,FOLIO='S-21',FILE='DISK131:[11ZAB1.11ZAB15101]DE15101A.;5',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_de15101_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_plan_of_distribution"> </A>
<A NAME="toc_de15101_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a controlled equity offering sales agreement with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor, under which we
may issue and sell up to 5,000,000 shares of our common stock from time to time through Cantor acting as agent. The form of the sales agreement will be filed as an exhibit to a report filed under the
Exchange Act and incorporated by reference in this prospectus supplement. The sales, if any, of shares made under the sales agreement will be made on the NASDAQ Global Market by means of ordinary
brokers' transactions at market prices, in block transactions or as otherwise agreed by Cantor and us. We may instruct Cantor not to sell common stock if the sales cannot be effected at or above the
price designated by us from time to time. We or Cantor may suspend the offering of common stock upon notice and subject to other conditions. As an agent, Cantor will not engage in any transactions
that stabilize the price of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay Cantor commissions for its services in acting as agent in the sale of common stock. Cantor will be entitled to compensation at a fixed commission rate up to 5.0% of the gross
sales price per share sold. Assuming the sale of all 5,000,000 shares of common stock being offered in this offering at an assumed offering price of $4.18 per share, which was the closing price of our
common stock as reported on the NASDAQ Global Market on January&nbsp;5, 2011, we estimate that the total expenses for the offering, excluding compensation payable to Cantor under the terms of the
sales agreement, will be approximately $175,000, which includes certain expense reimbursements payable to Cantor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
no event will the total amount of compensation paid to any member of the Financial Industry Regulatory Authority upon completion of this offering exceed 8.0% of the maximum gross
proceeds of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement
for sales of common stock will occur on the third business day following the date on which any sales are made, or on some other date that is agreed upon by us and Cantor in
connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
will act as sales agent on a commercially reasonable efforts basis. In connection with the sale of the common stock on our behalf, Cantor may, and will with respect to sales
effected in an "at the market offering," be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of Cantor may be deemed to be underwriting commissions or
discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to reimburse
Cantor for certain other specified expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offering pursuant to the sales agreement will terminate upon the earlier of (i)&nbsp;the sale of all common shares subject to the agreement, or (ii)&nbsp;termination of the sales
agreement as permitted therein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in
the future receive customary fees. To the extent required by Regulation&nbsp;M, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under
this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus supplement and the accompanying prospectus in electronic format may be made available on a web sites maintained by Cantor and Cantor may distribute the prospectus supplement
and the accompanying prospectus electronically. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=498044,FOLIO='S-22',FILE='DISK131:[11ZAB1.11ZAB15101]DE15101A.;5',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_de15101_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_legal_matters"> </A>
<A NAME="toc_de15101_4"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the securities being offered hereby will be passed upon by Lowenstein Sandler PC, Roseland, New Jersey. Cantor is being
represented in connection with this offering by DLA Piper&nbsp;LLP (US), New York, New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_experts"> </A>
<A NAME="toc_de15101_5"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of Celldex Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2009 and 2008 and for the years ended
December&nbsp;31, 2009 and 2008 and management's assessment of the effectiveness of internal control over financial reporting (which is included in Management's Report on Internal Control over
Financial Reporting) incorporated in this prospectus supplement and the accompanying prospectus by reference to the Annual Report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc.
for the year ended December&nbsp;31, 2009 have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp;
Young&nbsp;LLP, independent registered public accounting firm, has audited the consolidated statement of operations, stockholders' equity (deficit) and comprehensive
loss, and cash flows of Celldex Therapeutics,&nbsp;Inc. for the year ended December&nbsp;31, 2007 included in our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2009, which is incorporated by reference in this prospectus supplement and the accompanying prospectus and elsewhere in the registration statement. Those financial statements as of
December&nbsp;31, 2007, and for the year then ended, are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and
auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements of CuraGen Corporation, incorporated in this prospectus supplement and the accompanying prospectus by reference from CuraGen Corporation's Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008, as amended by Amendments No.&nbsp;1 and 2 to CuraGen's Annual Report on Form&nbsp;10-K for the year
ended December&nbsp;31, 2008 and the effectiveness of CuraGen Corporation's internal control over financial reporting, have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, an independent
registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm
given upon their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_where_you_can_find_more_information"> </A>
<A NAME="toc_de15101_6"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current
reports, proxy statements and other information with the SEC. You may read and copy these reports, proxy statements and other information at the SEC's public reference facilities at 100&nbsp;F
Street, N.E., Room&nbsp;1580, Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at
1-800-SEC-0330 for
more information about the operation of the public reference facilities. SEC filings are also available at the SEC's web site at </FONT><FONT SIZE=2><I>http://www.sec.gov.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompany prospectus are only part of a registration statement on Form&nbsp;S-3 that we have filed with the SEC under the Securities Act,
and therefore omit certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus
supplement and the accompanying prospectus, and you should refer to the applicable exhibit or schedule for a complete description of any statement referring to any contract or other document. You may
inspect a copy of the registration statement, including the exhibits and schedules, without charge, at the public reference room or obtain a copy from the SEC upon payment of the fees prescribed by
the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=533722,FOLIO='S-23',FILE='DISK131:[11ZAB1.11ZAB15101]DE15101A.;5',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<A NAME="page_de15101_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15101a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15101_incorporation_of_documents_by_reference"> </A>
<A NAME="toc_de15101_7"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" information that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement and accompanying prospectus. To the extent that any
statement that we make in this prospectus supplement is inconsistent with the statements made in the accompanying prospectus or the information incorporated by reference, the statements made in the
accompanying prospectus are deemed modified or superseded by the statements made in this prospectus supplement, while information that we file later with the SEC will automatically update and
supersede this information. We incorporate by reference into this prospectus supplement the documents listed below and any future filings we will make with the SEC under Sections&nbsp;13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this prospectus supplement but prior to the termination of the offering of the shares covered by this prospectus supplement and accompanying
prospectus (other than current reports furnished pursuant to Items&nbsp;2.02 and 7.01 of Form&nbsp;8-K). The documents we are incorporating by reference are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2009, filed with the SEC
on March&nbsp;12, 2010, as amended by Form&nbsp;10-K/A filed on March&nbsp;31, 2010 and by Form&nbsp;10-K/A filed on December&nbsp;23, 2010; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2010, June&nbsp;30,
2010, and September&nbsp;30, 2010, filed on May&nbsp;6, 2010, August&nbsp;5, 2010, and November&nbsp;4, 2010, respectively, and our Form&nbsp;10-Q/A filed on December&nbsp;23,
2010;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Current Reports on Form&nbsp;8-K filed on March&nbsp;30, 2010, May&nbsp;4, 2010 (except for the
information in Item&nbsp;2.02, which was not deemed filed), August&nbsp;4, 2010 (except for the information in Item&nbsp;2.02, which was not deemed filed), September&nbsp;7, 2010,
September&nbsp;16, 2010, November&nbsp;2, 2010 (except for the information in Item&nbsp;2.02, which was not deemed filed) and January&nbsp;6, 2011; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The description of our common stock contained in our Registration Statement on Form&nbsp;8-A, filed on
November&nbsp;8, 2004, as amended by Form&nbsp;8-A/A filed on October&nbsp;22, 2007 and March&nbsp;7, 2008. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should
direct any requests for documents to Celldex Therapeutics,&nbsp;Inc., Attention: Corporate Secretary, 119 Fourth Avenue, Needham, Massachusetts 02494, (781)&nbsp;433-0771. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide
you with information different from that contained or incorporated by reference in this prospectus supplement and accompanying prospectus. We are not making offers to sell the common stock in any
jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make
such offer or solicitation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=992212,FOLIO='S-24',FILE='DISK131:[11ZAB1.11ZAB15101]DE15101A.;5',USER='CDESORM',CD=';5-JAN-2011;17:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=5><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$150,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Depositary Shares<BR>
Units  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination
of (i)&nbsp;our common stock, (ii)&nbsp;our preferred stock, which we may issue in one or more series, (iii)&nbsp;warrants, (iv)&nbsp;depositary shares and (v)&nbsp;units, up to a maximum
aggregate offering price of $150,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer and sell these securities in amounts, at prices and on terms determined at the time of the offering. We will provide the specific terms of these securities in supplements to
this prospectus. You should read this prospectus and the accompanying prospectus supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully
before you make your investment decision. Our common stock is traded on the NASDAQ Global Select Market System under the symbol "CLDX." On March&nbsp;31, 2010, the last reported sale price of our
common stock on the NASDAQ Global Select Market System was $6.14 per share. You are urged to obtain current market quotations of the common stock. Each prospectus supplement will indicate if the
securities offered thereby will be listed on any securities exchange. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus may not be used to sell securities unless accompanied by a prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable prospectus
supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the
applicable prospectus supplement. For general
information about the distribution of securities offered, please see "Plan of Distribution" in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Investing in our securities involves risks. You should carefully review the information contained in this prospectus under the heading "Risk Factors" beginning on
page&nbsp;9 of this prospectus.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The date of this prospectus is April&nbsp;22, 2010. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=287556,FOLIO='blank',FILE='DISK132:[11ZAB2.11ZAB15102]BC15102A.;6',USER='LPALLES',CD=';4-JAN-2011;12:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg15102_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="BG15102A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg15102_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG15102_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi15102_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi15102_prospectus_summary"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi15102_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi15102_special_note_regarding_forward-looking_statements"><FONT SIZE=2><BR>
7</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de15102_risk_factors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de15102_risk_factors"><FONT SIZE=2><BR>
9</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIOS OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_use_of_proceeds"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_use_of_proceeds"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTIONS OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_descriptions_of_securities_we_may_offer"><FONT SIZE=2><BR>
22</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_description_of_common_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_description_of_common_stock"><FONT SIZE=2><BR>
23</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_description_of_preferred_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_description_of_preferred_stock"><FONT SIZE=2><BR>
24</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_description_of_warrants"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_description_of_warrants"><FONT SIZE=2><BR>
26</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg15102_description_of_depositary_shares"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg15102_description_of_depositary_shares"><FONT SIZE=2><BR>
28</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_description_of_units"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_description_of_units"><FONT SIZE=2><BR>
29</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_plan_of_distribution"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_plan_of_distribution"><FONT SIZE=2><BR>
29</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_incorporation_of_certain_documents_by_reference"><FONT SIZE=2><BR>
31</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_legal_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_legal_matters"><FONT SIZE=2><BR>
32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_experts"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_experts"><FONT SIZE=2><BR>
32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di15102_where_you_can_find_more_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di15102_where_you_can_find_more_information"><FONT SIZE=2><BR>
33</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <BR>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We have not authorized any person to give any information or make any statement that differs from what is in this prospectus. If any person does make a statement
that differs from what is in this prospectus, you should not rely on it. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any state in which
the offer or sale is not permitted. The information in this prospectus is complete and accurate as of its date, but the information may change after that date. You should not assume that the
information in this prospectus is accurate as of any date after its date.</B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=28,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=72207,FOLIO='2',FILE='DISK132:[11ZAB2.11ZAB15102]BG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi15102_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi15102_prospectus_summary"> </A>
<A NAME="toc_bi15102_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>PROSPECTUS SUMMARY    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing
a "shelf" registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under
this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement, including the exhibits and the documents incorporated or
deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2> as
described under the heading "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
time we sell securities pursuant to this prospectus, we will provide a prospectus supplement containing specific information about the terms of a particular offering by us. That
prospectus supplement may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement may add, update or change information in
this prospectus.
If the information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. You should read both this prospectus and, if
applicable, any prospectus supplement. See "Where You Can Find More Information" for more information. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this
prospectus or any prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any prospectus supplement. This
prospectus and any prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this
prospectus and any prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the
front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus
and any prospectus supplement is delivered or securities are sold on a later date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Unless this prospectus indicates otherwise or the context otherwise requires, the terms "we," "our," "us," "Celldex" or the "Company" as used in this prospectus
refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics,&nbsp;Inc. and not its subsidiaries in the sections entitled "Description
of Common Stock," "Description of Preferred Stock," "Description of Warrants," "Description of Depositary Shares," and "Description of Units."</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Company Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an integrated biopharmaceutical company that applies our comprehensive Precision Targeted Immunotherapy Platform to generate a
pipeline of candidates to treat cancer and other difficult-to-treat diseases. Our immunotherapy platform includes a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create novel disease-specific drug candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
strategy is to develop and demonstrate proof-of-concept for our product candidates before leveraging their value through partnerships or, in appropriate
situations, continuing late stage development through commercialization ourselves. Demonstrating proof-of-concept for a product candidate generally involves bringing it through
Phase&nbsp;1 clinical trials and one or more Phase&nbsp;2 clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=916902,FOLIO='3',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_bi15102_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>trials
so that we are able to demonstrate, based on human trials, good safety data for the product candidate and some data indicating its effectiveness. We thus leverage the value of our technology
portfolio through corporate, governmental and non-governmental partnerships. This approach allows us to maximize the overall value of our technology and product portfolio while best
ensuring the expeditious development of each individual product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;7, 2008, a wholly-owned subsidiary of Celldex (formerly named AVANT Immunotherapeutics,&nbsp;Inc.) merged into Celldex Research Corporation (formerly named Celldex
Therapeutics,&nbsp;Inc.), which was then a privately-held company. Through that merger, Celldex acquired a therapeutic cancer vaccine candidate, known as CDX-110, which is
currently in Phase&nbsp;2 development for the treatment of glioblastoma multiforme. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;1, 2009, a wholly-owned subsidiary of Celldex (which we refer to as the Merger Sub), merged with and into CuraGen Corporation ("CuraGen"), which we refer to as the
CuraGen Merger, in accordance with the Agreement and Plan of Merger, dated May&nbsp;28, 2009, among CuraGen, Merger Sub and Celldex, which we refer to as the Merger Agreement. As a result of the
Merger, CuraGen became a wholly-owned subsidiary of Celldex. Through the CuraGen Merger, Celldex acquired over $70&nbsp;million in cash, cash equivalents and marketable securities and an antibody
drug candidate, known as CDX-011, which is currently in Phase&nbsp;2 development for treatment of metastatic melanoma and breast cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;31, 2009, CuraGen merged into Celldex and, as a result of the merger, Celldex succeeded to all of CuraGen's assets and liabilities and the separate existence of
CuraGen ceased. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Current Programs and Partnerships  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading developer of innovative products that we call Precision Targeted Immunotherapeutics which are designed
to address major unmet health care needs. Most of our products are derived from a broad set of complementary technologies (collectively known as our Precision Targeted Immunotherapy Platform). This
platform includes monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create novel disease-specific drugs. We are using our Precision
Targeted Immunotherapy Platform to
develop targeted immunotherapies that prevent or treat specific forms of cancer, autoimmune disorders and disease caused by infectious organisms. We expect that a large percentage of our research and
development expenses will be incurred in support of our current and future clinical trial programs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=76539,FOLIO='4',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_bi15102_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the programs that we currently believe are material to our business: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="10pt" style="font-family:times;"></TD>
<TD WIDTH="21%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:62pt;"><FONT SIZE=1><B>Product (generic)

<!-- COMMAND=ADD_SCROPPEDRULE,62pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Indication/Field </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Partner </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-110 (rindopepimut)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Glioblastoma multiforme</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>Pfizer (PF-4948568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2b</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-011 (glembatumumab vedotin)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Metastatic melanoma and breast cancer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Colorectal, bladder, pancreas, ovarian and breast tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Multiple solid tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Phase 1/2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2 style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PRECLINICAL</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cancer, autoimmune disease and transplant</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Immuno-modulation, multiple tumors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal and ovarian cancer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Renal disease</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Preclinical</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2 VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>MARKETED PRODUCTS</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rotarix&reg;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Rotavirus infection</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>GlaxoSmithKline</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Marketed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> Clinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-110  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead clinical development program, CDX-110, is a peptide-based immunotherapy that targets the tumor specific molecule
called EGFRvIII, a functional variant of the naturally expressed epidermal growth factor receptor ("EGFR"), a protein which has been well validated as a target for cancer therapy. Unlike EGFR,
EGFRvIII is not present in normal tissues, and has been shown to be a transforming oncogene that can directly contribute to the cancer cell growth. EGFRvIII is commonly present in glioblastoma
multiforme, or GBM, the most common and aggressive form of brain cancer, and has also been observed in various other cancers such as breast, ovarian, prostate, colorectal, and head&nbsp;&amp; neck
cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2008, we and Pfizer&nbsp;Inc. ("Pfizer") entered into a License and Development Agreement (the "Pfizer Agreement") under which Pfizer was granted an exclusive worldwide
license to CDX-110. The Pfizer Agreement also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other potential indications. Pfizer funds all development costs for these
programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-011  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-011 (formerly CR011-vcMMAE) is an antibody-drug conjugate (ADC) that consists of a fully-human
monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB or (GPNMB) that is expressed in a
variety of human cancers including breast cancer and melanoma. The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle
Genetics,&nbsp;Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CDX-011 targets and binds to&nbsp;GPNMB and upon internalization into the
targeted cell, CDX-011 is designed to release MMAE from CR011 to produce a cell-killing effect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=555827,FOLIO='5',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_bi15102_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1307  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead APC Targeting Technology&#153; product candidate, CDX-1307, is in development for the treatment of
epithelial tumors such as colorectal, pancreatic, bladder, ovarian and breast cancers. CDX-1307 targets the beta chain of human chorionic gonadotropin, known as hCG-Beta, which
is an antigen often found in epithelial tumors. The presence of hCG-Beta in these cancers correlates with a poor clinical outcome, suggesting that this molecule may contribute to tumor
growth. Normal adult tissues have minimal expression of hCG-Beta; therefore, targeted immune responses are not expected to generate significant side effects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1401  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell
receptor, DEC-205, linked to the NY-ESO-1 tumor antigen. In humans, NY-ESO-1 has been detected in 20&nbsp;-&nbsp;30% of
cancers, thus representing a broad opportunity. This product is intended to selectively deliver the NY-ESO-1 antigen to APCs for generating robust immune responses against
cancer cells expressing NY-ESO-1. Unlike CDX-1307, which targets the mannose receptor expressing dendritic cells, CDX-1401 is the first APC product
targeting DEC-205 expressing dendritic cells. We are developing CDX-1401 for the treatment of malignant melanoma and a variety of solid tumors which express the proprietary
cancer antigen NY-ESO-1, which we licensed from the Ludwig Institute for Cancer Research in 2006. We believe that preclinical studies have shown that CDX-1401 is
effective for activation of human T-cell responses against NY-ESO-1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1135  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-1135 is a molecule that inhibits a part of the immune system called the complement system. The complement system is a
series of proteins that are important initiators of the body's acute inflammatory response against disease, infection and injury. Excessive complement activation also plays a role in some persistent
inflammatory conditions. CDX-1135 is a soluble form of naturally occurring Complement Receptor 1 that inhibits the activation of the complement cascade in animal models and in human
clinical trials. We believe that regulating the complement system could have therapeutic and prophylactic applications in several acute and chronic conditions, including organ transplantation,
multiple sclerosis, rheumatoid arthritis, age-related macular degeneration ("AMD"), atypical Hemolytic Uremic Syndrome ("aHUS"), Paroxysmal Nocturnal Hemaglobinuria ("PNH"), Dense Deposit
Disease ("DDD") in kidneys, and myasthenia gravis. We are currently defining the most appropriate clinical development path for CDX-1135 and are focusing on rare disease conditions of
unregulated complement activation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Preclinical Development Programs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-301  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-301 is a FMS-like tyrosine kinase 3 ligand (Flt3L) that we licensed from Amgen in March 2009.
CDX-301 is a growth factor for stem cells and immune cells called dendritic cells. Based on previous experience with this molecule, we believe that CDX-301 has considerable
opportunity in various transplant settings as a stem cell mobilizing agent. In addition, CDX-301 is an immune modulating molecule that increases the numbers and activity of specific types
of immune cells. We believe CDX-301 has significant opportunity for synergistic development in combination with proprietary molecules in our portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-1127  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a License Agreement with the University of Southampton, UK, to develop human antibodies to CD27, a potentially
important target for immunotherapy of various cancers. In </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=518192,FOLIO='6',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_bi15102_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>preclinical
models, antibodies to CD27 alone have been shown to mediate anti-tumor effects, and may be particularly effective in combination with other immunotherapies. CD27 is a critical
molecule in the activation pathway of lymphocytes. It is downstream from CD40, and may provide a novel way to regulate the immune responses. Engaging CD27 with the appropriate monoclonal antibody has
proven highly effective at promoting anti-cancer immunity in mouse models. We are evaluating new human monoclonal antibodies in preclinical models. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> CDX-014  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDX-014 (formerly CR014-vcMMAE) is a fully-human monoclonal ADC that targets TIM-1, an
immunomudulatory protein that appears to down regulate immune response to tumors. The antibody, CDX-014, is linked to a potent chemotherapeutic, monomethyl auristatin E (MMAE), using
Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into TIM-1-expressing tumor cells,
resulting in a targeted cell-killing effect. CDX-014 has shown potent activity in preclinical models of ovarian and renal cancer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> CDX-1189  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing therapeutic human antibodies to a signaling molecule known as CD89 or Fc<FONT FACE="SYMBOL">a</FONT>
receptor type&nbsp;I (Fc<FONT FACE="SYMBOL">a</FONT>RI). CD89 is expressed by some white blood cells and leukemic cell lines, and has been shown to be important in controlling
inflammation and tumor growth in animal models. We have proprietary, fully human antibodies to CD89 in preclinical development. Depending upon the specific antibody used, anti-CD89
antibodies can either be activating and thus stimulate immune responses, or down-regulating and act as an anti-inflammatory agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Marketed Products  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Rotavirus Vaccine  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rotavirus is a major cause of diarrhea and vomiting in infants and children. In 1997, we licensed our oral rotavirus strain to
GlaxoSmithKline, or Glaxo, and Glaxo assumed responsibility for all subsequent clinical trials and all other development activities. Glaxo gained approval for its rotavirus vaccine,
Rotarix&reg;, in Mexico in July 2004, which represented the first in a series of worldwide approvals and commercial launches for the product leading up to the approval in Europe in 2006 and in
the U.S. in 2008. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Corporate Information  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. The principal executive offices of Celldex are located at 119 Fourth Avenue, Needham,
Massachusetts 02494 and its telephone number is (781)&nbsp;433-0771. Our corporate website is </FONT><FONT SIZE=2><I>www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. The information
on our website is not incorporated by reference into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi15102_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_bi15102_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Any statements about our expectations, beliefs, plans, objectives, assumptions or future
events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as "anticipate," "estimate,"
"plans," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar words or phrases. Accordingly, these statements involve estimates, assumptions and
uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=10608,FOLIO='7',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_bi15102_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>risk
factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the
statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including
the factors described in the section entitled "Risk Factors" in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise
any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and
risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in
this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=913082,FOLIO='8',FILE='DISK132:[11ZAB2.11ZAB15102]BI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de15102_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15102_risk_factors"> </A>
<A NAME="toc_de15102_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>An investment in our securities involves risks. Before making an investment decision, you should carefully
consider the risks described under "Risk Factors" in this prospectus as well as the applicable prospectus supplement and in our most recent Annual Report on Form&nbsp;10-K, and in our
updates to those Risk Factors in our Quarterly Reports on Form&nbsp;10-Q following the most recent Form&nbsp;10-K, and in all other information appearing in this prospectus
or incorporated by reference into this prospectus and any applicable prospectus supplement. The material risks and uncertainties that management believes affect us will be described in those
documents. In addition to those risk factors, there may be additional risks and uncertainties of which management is not aware or focused on or that management deems immaterial. Our business,
financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose
all or part of your investment. This prospectus is qualified in its entirety by these risk factors.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to Our Business  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our products and product candidates are subject to extensive regulatory scrutiny.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our products and product candidates are at various stages of development and commercialization and our activities, products and
product candidates are significantly regulated by a number of governmental entities, including the Food and Drug Administration in the United States, which we refer to as the FDA, and by comparable
authorities in other countries. These entities regulate, among other things, the manufacture, testing, safety, effectiveness, labeling, documentation, advertising and sale of our products and product
candidates. We or our partners must obtain regulatory approval for a product candidate in all of these areas before we can commercialize a product candidate. Product development within this regulatory
framework takes a number of years and involves the expenditure of substantial resources. This process typically requires extensive preclinical and clinical testing, which may take longer or cost more
than we anticipate, and may prove unsuccessful due to numerous factors. Many product candidates that initially appear promising ultimately do not reach the market because they are found to be unsafe
or ineffective when tested. Companies in the pharmaceutical, biotechnology and vaccines industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising
results in earlier trials. Our inability to commercialize a product or product candidate would impair our ability to earn future revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If our products do not pass required tests for safety and effectiveness, we will not be able to derive commercial revenue from them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to succeed, we will need to derive commercial revenue from the products we have under development. The FDA has not approved
our CDX-110 or CDX-011 product candidates or any of our other lead products for sale to date. Products in our vaccine programs are in various stages of preclinical and clinical
testing. Preclinical tests are performed at an early stage of a product's development and provide information about a product's safety and effectiveness on laboratory animals. Preclinical tests can
last years. If a product passes its preclinical tests satisfactorily, and we determine that further development is warranted, we would file an investigational new drug application for the product with
the FDA, and if the FDA gives its approval we would begin Phase&nbsp;1 clinical tests. Phase&nbsp;1 testing generally lasts between 6 and 24&nbsp;months. If Phase&nbsp;1 test results are
satisfactory and the FDA gives its approval, we can begin Phase&nbsp;2 clinical tests. Phase&nbsp;2 testing generally lasts between 6 and 36&nbsp;months. If Phase&nbsp;2 test results are
satisfactory and the FDA gives its approval, we can begin Phase&nbsp;3 pivotal studies. Phase&nbsp;3 studies generally last between 12 and 48&nbsp;months. Once clinical testing is completed and
a new drug application is filed with the FDA, it may take more than a year to receive FDA approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=509648,FOLIO='9',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases we must show that a pharmaceutical product is both safe and effective before the FDA, or drug approval agencies of other countries where we intend to sell the product, will
approve it for sale. Our research and testing programs must comply with drug approval requirements both in the United States and in other countries, since we are developing our lead products with
companies, including Glaxo and Pfizer, which intend to or could later decide to commercialize them both in the U.S. and abroad. A product may fail for safety or effectiveness at any stage of the
testing process. A major risk we face is the possibility that none of our products under development will come through the testing process to final approval for sale, with the result that we cannot
derive any commercial revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Product testing is critical to the success of our products but subject to delay or cancellation if we have difficulty enrolling patients.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our portfolio of potential products moves from preclinical testing to clinical testing, and then through progressively larger and
more complex clinical trials, we will need to enroll an increasing number of patients with the appropriate characteristics. At times we have experienced difficulty enrolling patients and we may
experience more difficulty as the scale of our clinical testing program increases. The factors that affect our ability to enroll patients are largely uncontrollable and include principally the
following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the nature of the clinical test;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the size of the patient population;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>patients' willingness to receive a placebo or less effective treatment on the control arm of a clinical study; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the distance between patients and clinical test sites; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the eligibility criteria for the trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot enroll patients as needed, our costs may increase or it could force us to delay or terminate testing for a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Any delay in obtaining regulatory approval would have an adverse impact on our ability to earn future revenues.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that none of the products or product candidates that we develop will obtain the regulatory approvals necessary for us to
begin commercializing them. The time required to obtain FDA and other approvals is unpredictable but often can take years following the commencement of clinical trials, depending upon the nature of
the product candidate. Any analysis we perform of data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory
approval. Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular product candidate. Furthermore, if we, or
our partners, do not reach the market with our products before our competitors offer products for the same or similar uses, or if we, or our partners, are not effective in marketing our products, our
revenues from product sales, if any, will be reduced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face intense competition in our development activities. We face competition from many companies in the United States and abroad, including a number of large pharmaceutical companies,
firms specialized in the development and production of vaccines, adjuvants and vaccine and immunotherapeutic delivery systems and major universities and research institutions. These competitors
include Alexion, Anadys, Antigenics, Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent, Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck, NeoPharm, Northwest </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=972540,FOLIO='10',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>Biotherapeutics,
Novavax, Pfizer, Roche, Sanofi-Aventis, Seattle Genetics, and Vical. Most of our competitors have substantially greater resources, more extensive experience in conducting preclinical
studies and clinical testing and obtaining regulatory approvals for their products, greater operating experience, greater research and development and marketing capabilities and greater production
capabilities than those of ours. These companies might succeed in obtaining regulatory approval for competitive products more rapidly than we can for our products, especially if we experience any
delay in obtaining required regulatory approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Failure to comply with applicable regulatory requirements would adversely impact our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even after receiving regulatory approval, our products would be subject to extensive regulatory requirements, and our failure to comply
with applicable regulatory requirements will adversely impact our operations. In the United States, the FDA requires that the manufacturing facility that produces a product meet specified standards,
undergo an inspection and obtain an establishment license prior to commercial marketing. Subsequent discovery of previously unknown problems with a product or its manufacturing process may result in
restrictions on the product or the manufacturer, including withdrawal of the product from the market. Failure to comply with the applicable regulatory requirements can result in fines, suspensions of
regulatory approvals, product recalls, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We depend greatly on the intellectual capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our
products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loss of Anthony S. Marucci, our President and Chief Executive Officer, or other key members of our staff, including Avery W.
Catlin, our Chief Financial Officer, Dr.&nbsp;Thomas Davis, our Chief Medical Officer, or Dr.&nbsp;Tibor Keler, our Chief Scientific Officer, could harm us. We entered into employment agreements
with Messrs.&nbsp;Marucci, Catlin, Davis and Keler. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability
to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial and marketing personnel, particularly as
we expand our activities in clinical trials, the regulatory approval process and sales and manufacturing. We routinely enter into consulting agreements with our scientific and clinical collaborators
and advisors, opinion leaders and heads of academic departments in the ordinary course of our business. We also enter into contractual agreements with physicians and institutions who recruit patients
into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for this type of personnel from other companies,
research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on contract manufacturers. Should the cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers vary to our
disadvantage, our business operations could suffer significant harm.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have small-lot manufacturing capability at our Fall River facility, we rely on sourcing from third-party
manufacturers for suitable quantities of some of our clinical and commercial grade materials essential to preclinical and clinical studies currently underway and to planned clinical trials in addition
to those currently being conducted by third parties
or us. The inability to have suitable quality and quantities of these essential materials produced in a timely manner would result in significant delays in the clinical development and
commercialization of products, which could adversely affect our business, financial condition and results of operations. We also rely on collaborators and contract manufacturers to manufacture
proposed products in both clinical and commercial quantities in the future. Our leading vaccine candidates require specialized manufacturing capabilities and processes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=271053,FOLIO='11',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may face difficulty in securing commitments from U.S. and foreign contract manufacturers as these manufacturers could be unwilling or unable to accommodate our needs. Relying on
foreign manufacturers involves peculiar and increased risks, including the risk relating to the difficulty foreign manufacturers may face in complying with the FDA's Good Manufacturing Practices
("GMP") as a result of language barriers, lack of familiarity with GMP or the FDA regulatory process or other causes, economic or political instability in or affecting the home countries of our
foreign manufacturers, shipping delays, potential changes in foreign regulatory laws governing the sales of our product supplies, fluctuations in foreign currency exchange rates and the imposition or
application of trade restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurances that we will be able to enter into long-term arrangements with third party manufacturers on acceptable terms, or at all. Further, contract
manufacturers must also be able to meet our timetable and requirements, and must operate in compliance with GMP; failure to do so could result in, among other things, the disruption of product
supplies. As noted above, non-U.S. contract manufacturers may face special challenges in complying with the FDA's GMP requirements, and although we are not currently dependent on
non-U.S. collaborators or contract manufacturers, we may choose or be required to rely on non-U.S. sources in the future as we seek to develop stable supplies of increasing
quantities of materials for ongoing clinical trials of larger scale. Our dependence upon third parties for the manufacture of our products may adversely affect our profit margins and our ability to
develop and deliver products on a timely and competitive basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
significant third-parties who we currently rely on for sourcing of suitable quantities of some of our clinical and commercial grade materials include: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pfizer, Bayer, and Genzyme for the CDX-110 drug product;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dalton for Hiltonol which is an integral part of several of our drug products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>3M for Resiquimod which is an integral part of several of our drug products; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Piramal for the CDX-011 drug product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or our third-party manufacturers are unable to produce drug material in suitable quantities of appropriate quality, in a timely manner, and at a feasible cost, our clinical tests
will face delays. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on third parties to plan, conduct and monitor our clinical tests, and their failure to perform as required would interfere with our product development.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on third parties to conduct a significant portion of our clinical development activities. These activities include clinical
patient recruitment and observation, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. We conduct project management and medical and safety
monitoring in-house for some of our programs and rely on third parties for the remainder of our clinical development activities. Our significant third-party clinical development providers
include Pfizer for the development of our CDX-110 drug product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these third parties fails to perform as we expect or if their work fails to meet regulatory standards, our testing could be delayed, cancelled or rendered ineffective. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> We depend greatly on third party collaborators to license, develop and commercialize some of our products, and they may not meet our expectations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreements with companies, including Glaxo, Pfizer and VTI for the licensing, development and ultimate commercialization of
some of our products. Some of those agreements give substantial responsibility over the products to the collaborator. Some collaborators may be unable or unwilling to devote sufficient resources to
develop our products as their agreements require. They often face business risks similar to ours, and this could interfere with their efforts. Also, collaborators may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1043640,FOLIO='12',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>choose
to devote their resources to products that compete with ours. If a collaborator does not successfully develop any one of our products, we will need to find another collaborator to do so. The
success of our search for a new collaborator will depend on our legal right to do so at the time and whether the product remains commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
success of our products depends in great part upon our and our collaborators' success in promoting them as superior to other treatment alternatives. We believe that our products can
be proven to offer disease prevention and treatment with notable advantages over drugs in terms of patient compliance and effectiveness. However, there can be no assurance that we will be able to
prove these advantages or that the advantages will be sufficient to support the successful commercialization of our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may face delays, difficulties or unanticipated costs in establishing sales, distribution and manufacturing capabilities for our commercially ready products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have chosen to retain, rather than license, all rights to some of our lead products, such as CDX-011 and our
APC Targeting Technology programs. If we proceed with this strategy, we will have full responsibility for commercialization of these products if and when they are approved for sale. We currently lack
the marketing, sales and distribution capabilities that we will need to carry out this strategy. To market any of our products directly, we must develop a substantial marketing and sales force with
technical expertise and a supporting distribution capability. We have little expertise in this area, and we may not succeed. We may find it necessary to enter into strategic partnerships on uncertain
but potentially unfavorable terms to sell, market and distribute our products when they are approved for sale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our products are difficult to manufacture, especially in large quantities, and we have not yet developed commercial scale manufacturing processes for any of our products. We do
not currently plan to develop internal manufacturing capabilities to produce any of our products at commercial scale if
they are approved for sale. To the extent that we choose to market and distribute these products ourselves, this strategy will make us dependent on other companies to produce our products in adequate
quantities, in compliance with regulatory requirements, and at a competitive cost. We may not find third parties capable of meeting those manufacturing needs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Certain factors could negatively affect the demand for and sales and profitability of Rotarix&reg;, which would have a material adverse affect on our revenues.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Both the demand and ultimately the profitability of Rotarix&reg; are components to our success. We have licensed a rotavirus
strain to Glaxo for the purposes of Glaxo developing and commercializing their Rotarix&reg; vaccine worldwide. Glaxo gained approval for Rotarix&reg; in Mexico in July 2004, in the
European Union in February 2006 and in the United States in April 2008. In May 2005, we entered into an agreement whereby an affiliate of Paul Royalty Fund, or PRF, purchased an interest in the net
royalties we will receive on worldwide sales of Rotarix&reg;. In addition, we retain upside participation in the worldwide net royalties from Rotarix&reg; once, and if, PRF receives an
agreed upon return on capital invested (2.45 times PRF's aggregate cash payments to us of $60&nbsp;million). The following are potential factors, among others, that may negatively affect the demand
for Rotarix&reg;: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Competitors in the pharmaceuticals, biotechnology and vaccines market have greater financial and management resources, and
significantly more experience in bringing products to market, and may develop, manufacture and market products that are more effective or less expensive than Rotarix&reg;; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Rotarix&reg; could be replaced by a novel product and may become obsolete; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=630189,FOLIO='13',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Glaxo may be unable to prevent third parties from infringing upon their proprietary rights related to
Rotarix&reg;;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Users may not accept such a recently approved product without years of proven history; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We are dependent on Glaxo for the manufacturing, testing, acquisition of regulatory approvals, marketing, distribution and
commercialization of Rotarix&reg;. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on the sales of Rotarix&reg; and our results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Other factors could affect the demand for and sales and profitability of Rotarix&reg; and any other of our current or future products.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, other factors that could affect the demand for and sales and profitability of our products include, but are not limited
to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The timing of regulatory approval, if any, of competitive products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our, Glaxo's, Pfizer's or any other of our partners' pricing decisions, as applicable, including a decision to increase or
decrease the price of a product, and the pricing decisions of our competitors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Government and third-party payer reimbursement and coverage decisions that affect the utilization of our products and
competing products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Negative safety or efficacy data from new clinical studies conducted either in the U.S. or internationally by any party
could cause the sales of our products to decrease or a product to be recalled;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The degree of patent protection afforded our products by patents granted to or licensed by us and by the outcome of
litigation involving our or any of our licensor's patents;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The outcome of litigation involving patents of other companies concerning our products or processes related to production
and formulation of those products or uses of those products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The increasing use and development of alternate therapies;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The rate of market penetration by competing products; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The termination of, or change in, existing arrangements with our partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors could have a material adverse effect on Glaxo's sales of Rotarix&reg; and on any other of our current or future products and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We may be unable to manage multiple late stage clinical trials for a variety of product candidates simultaneously.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue
developing all of our current products. The management of late stage clinical trials is more complex and time consuming than early stage trials. Typically early stage trials involve several hundred
patients in no more than 10-30 clinical sites. Late stage (Phase&nbsp;3) trials may involve up to several thousand patients in up to several hundred clinical sites and may require
facilities in several countries. Therefore, the project management required to supervise and control such an extensive program is substantially larger than early stage programs. As the need for these
resources is not known until some months before the trials begin it is necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this
team to be recruited quickly the sponsor is faced with a decision to delay the program or to initiate it </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=647529,FOLIO='14',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>with
inadequate management resources. This may result in recruitment of inappropriate patients, inadequate monitoring of clinical investigators and inappropriate handling of data or data analysis.
Consequently it is possible that conclusions of efficacy or safety may not be acceptable to permit filing of a Biologic License Application ("BLA") or New Drug Application ("NDA") for any one of the
above reasons or a combination of several. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We face the risk of product liability claims, which could exceed our insurance coverage, and produce recalls, each of which could deplete our cash resources.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a participant in the pharmaceutical, biotechnology and vaccines industries, we are exposed to the risk of product liability claims
alleging that use of our products or product candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or sale of our products or
product candidates and may be made directly by patients involved in clinical trials of our products, by consumers or healthcare providers or by individuals, organizations or companies selling our
products. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance
covering product liability claims becomes increasingly expensive as a product candidate moves through the development pipeline to commercialization. Under our license
agreements, we are required to maintain clinical trial liability insurance coverage up to $14&nbsp;million. However, there can be no assurance that such insurance coverage is or will continue to be
adequate or available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaborative agreements to increase our insurance coverage in the future. We may not be
able to secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any
liability for damages resulting from a product liability claim could exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material
adverse effect on our business, financial condition and results of operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business
and inhibit or prevent commercialization of other products and product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, some of our licensing and other agreements with third parties require or might require us to maintain product liability insurance. If we cannot maintain acceptable amounts
of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material
adverse impact on our operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements
with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements will typically restrict the ability of our
collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are
notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are typically
controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint research and development programs which may require us to share trade secrets
under the terms of research and development partnership or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach
of these agreements, independent development or publication of information including our trade secrets in cases </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=368546,FOLIO='15',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>where
we do not have proprietary or otherwise protected rights at the time of publication. A competitor's discovery of our trade secrets would impair our competitive position. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> We may not be able to successfully integrate newly-acquired technology with our existing technology or to modify our technologies to create new vaccines.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our acquisition of technology assets from entities such as 3M Company and Amgen, we have acquired access to
Resiquimod&#153; (a TLR 7/8 agonist) and Flt3L, which may improve the immunogenicity of our vaccines. If we are able to integrate these licensed assets with our vaccine technologies, we believe
these assets will give our vaccines a competitive advantage. However, if we are unable to successfully integrate licensed assets, or other technologies which we have acquired or may acquire in the
future, with our existing technologies and potential products currently under development, we may be unable to realize any benefit from our acquisition of these assets, or other technologies which we
have acquired or may acquire in the future and may face the loss of our investment of financial resources and time in the integration process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that our vaccine technology portfolio may offer opportunities to develop vaccines that treat a variety of oncology, inflammatory and infectious diseases by stimulating a
patient's immune system against those disease organisms. If our vaccine technology portfolio cannot be used to create effective vaccines against a variety of disease organisms, we may lose all or
portions of our investment in development efforts for new vaccine candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We license technology from other companies to develop products, and those companies could influence research and development or restrict our use of it.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Companies that license technologies to us that we use in our research and development programs may require us to achieve milestones or
devote minimum amounts of resources to develop products using those technologies. They may also require us to make significant royalty and milestone payments, including a percentage of any
sublicensing income, as well as payments to reimburse them for patent costs. The number and variety of our research and development programs require us to establish priorities and to allocate
available resources among competing programs. From time to time we may choose to slow down or cease our efforts on particular products. If in doing so we fail to fully perform our obligations under a
license, the licensor can terminate the licenses or permit our competitors to use the technology. Moreover, we may lose our right to market and sell any products based on the licensed technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> We have many competitors in our field and they may develop technologies that make ours obsolete.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology, pharmaceuticals and therapeutics are rapidly evolving fields in which scientific and technological developments are
expected to continue at a rapid pace. We have many competitors in the U.S. and abroad. These competitors include Alexion, Anadys, Antigenics,
Baxter, BioSante, Crucell, Dendreon, Eli Lilly, Emergent, Genitope, GlaxoSmithKline, Idera, Intercell, Immunogen, Maxygen, Merck, NeoPharm, Northwest Biotherapeutics, Novavax, Pfizer, Roche,
Sanofi-Aventis, Seattle Genetics, and Vical. Our success depends upon our ability to develop and maintain a competitive position in the product categories and technologies on which we focus. Many of
our competitors have greater capabilities, experience and financial resources than we do. Competition is intense and is expected to increase as new products enter the market and new technologies
become available. Our competitors may: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>develop technologies and products that are more effective than ours, making ours obsolete or otherwise noncompetitive; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain regulatory approval for products more rapidly or effectively than us; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=831550,FOLIO='16',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>obtain patent protection or other intellectual property rights that would block our ability to develop competitive
products. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> We rely on patents, patent applications and other intellectual property protections to protect our technology and trade secrets; which are expensive and may not provide
sufficient protection.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in part on our ability to obtain and maintain patent protection for technologies that we use. Biotechnology patents
involve complex legal, scientific and factual questions and are highly uncertain. To date, there is no consistent policy regarding the breadth of claims allowed in biotechnology patents, particularly
in regard to patents for technologies for human uses like those we use in our business. We cannot predict whether the patents we seek will issue. If they do issue, a competitor may challenge them and
limit their scope. Moreover, our patents may not afford effective protection against competitors with similar technology. A successful challenge to any one of our patents could result in a third
party's ability to use the technology covered by the patent. We also face the risk that others will infringe, avoid or circumvent our patents. Technology that we license from others is subject to
similar risks and this could harm our ability to use that technology. If
we, or a company that licenses technology to us, were not the first creator of an invention that we use, our use of the underlying product or technology will face restrictions, including elimination. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we must defend against suits brought against us or prosecute suits against others involving intellectual property rights, we will incur substantial costs. In addition to any potential
liability for significant monetary damages, a decision against us may require us to obtain licenses to patents or other intellectual property rights of others on potentially unfavorable terms. If
those licenses from third parties are necessary but we cannot acquire them, we would attempt to design around the relevant technology, which would cause higher development costs and delays, and may
ultimately prove impracticable </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our business requires us to use hazardous materials, which increases our exposure to dangerous and costly accidents.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development activities involve the use of hazardous chemicals, biological materials and radioactive compounds.
Although we believe that our safety procedures for handling and disposing of hazardous materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate
the risk of accidental contamination or injury from these materials. In the event of an accident, an injured party will likely sue us for any resulting damages with potentially significant liability.
The ongoing cost of complying with environmental laws and regulations is significant and may increase in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Health care reform and restrictions on reimbursement may limit our returns on potential products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because our strategy ultimately depends on the commercial success of our products, we assume, among other things, that end users of our
products will be able to pay for them. In the United States and other countries, in most cases, the volume of sales of products like those we are developing depends on the availability of
reimbursement from third-party payors, including national health care agencies, private health insurance plans and health maintenance organizations. Third-party payors increasingly challenge the
prices charged for medical products and services. Accordingly, if we succeed in bringing products to market, and reimbursement is not available or is insufficient, we could be prevented from
successfully commercializing our potential products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
health care industry in the United States and in Europe is undergoing fundamental changes as a result of political, economic and regulatory influences. Reforms proposed from time to
time include mandated basic health care benefits, controls on health care spending, the establishment of governmental controls over the cost of therapies, creation of large medical services and
products </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=43,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=79679,FOLIO='17',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>purchasing
groups and fundamental changes to the health care delivery system. We anticipate ongoing review and assessment of health care delivery systems and methods of payment in the United States
and other countries. We cannot predict whether any particular reform initiatives will result or, if adopted, what their impact on us will be. However, we expect that adoption of any reform proposed
will impair our ability to market products at acceptable prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Changes in laws affecting the health care industry could adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., there have been numerous proposals considered at the federal and state levels for comprehensive reforms of health care and
its cost, and it is likely that federal and state legislatures and health agencies will continue to focus on health care reform in the future. In March 2010, the U.S. passed legislation to reform the
U.S. health care system by expanding health insurance coverage, reducing certain health care costs and making other changes. While this and continued health care reform may increase the number of
patients who have insurance coverage for our products, it may also include cost containment measures that adversely affect reimbursement for our products, including:  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>change the Medicare reimbursement system for outpatient drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>increase the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>facilitate the importation of lower-cost prescription drugs that are marketed outside the U.S. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and
requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some
cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may
result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and our collaborators and partners operate in a highly regulated industry. As a result, governmental actions may adversely affect our business, operations or financial condition,
including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to
health care availability, method of delivery and payment for health care products and services;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and
result in lost market opportunity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on
product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of
approved products, or otherwise adversely affect the market for our products;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>new laws, regulations and judicial decisions affecting pricing or marketing practices; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>changes in the tax laws relating to our operations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enactment in the U.S. of health care reform, possible legislation which could ease the entry of competing follow-on biologics in the marketplace, new legislation or
implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of
previously enacted and possible future changes in laws that could adversely affect our business. In addition, the Food and Drug Administration </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=44,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=173526,FOLIO='18',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Amendments
Act of 2007 included new authorization for the FDA to require post-market safety monitoring, along with an expanded clinical trials registry and clinical trials results
database, and expanded authority for the FDA to impose civil monetary penalties on companies that fail to meet certain commitments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If physicians, patients and third-party payors do not accept any future drugs that we may develop, we may be unable to generate significant revenue, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if our drug candidates as well as any drug candidates that we may develop or acquire in the future obtain regulatory approval,
they may not gain market acceptance among physicians, patients and health care payors. Physicians may elect not to recommend these drugs for a variety of reasons including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>timing of market introduction of competitive drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lower demonstrated clinical safety and efficacy compared to other drugs;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of cost-effectiveness;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>lack of availability of reimbursement from third-party payors;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>convenience and ease of administration;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>prevalence and severity of adverse side effects;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>other potential advantages of alternative treatment methods; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ineffective marketing and distribution support. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our approved drugs fail to achieve market acceptance, we would not be able to generate sufficient revenue from product sales to maintain or grow our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we are not successful in integrating CuraGen's drug development programs, we may not be able to operate efficiently after the CuraGen Merger, which may have a material
adverse effect on our results of operations and financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Achieving the benefits of the CuraGen Merger will depend in part on the successful integration of CuraGen's clinical and preclinical
programs and personnel in a timely and efficient manner. The integration process requires coordination of different development, regulatory, and manufacturing teams, and involves the integration of
systems, applications, policies, procedures, business processes and operations. This may be difficult and unpredictable because of possible cultural conflicts and different opinions on scientific and
regulatory matters. If we cannot successfully integrate CuraGen's programs and personnel, we may not realize the expected benefits of the CuraGen Merger. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Integrating CuraGen's programs may divert management's attention away from our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The successful integration of CuraGen's programs and personnel may place a significant burden on our management and internal resources,
including time that will be spent on winding down CuraGen's facility in Connecticut and transitioning certain CuraGen employees to our facilities. The diversion of management's attention and any
difficulties encountered in the transition and integration process could result in delays in our clinical trial programs and could otherwise harm our business, financial condition and operating
results. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=45,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=633799,FOLIO='19',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Risks Related to Our Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> Our history of losses and uncertainty of future profitability make our securities a highly speculative investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have had no commercial revenues to date from sales of our human therapeutic or vaccine products and cannot predict when we will. We
have an accumulated deficit of $157.7&nbsp;million as of December&nbsp;31, 2009. We expect to spend substantial funds to continue the research and development testing of our products that we have
in the preclinical and clinical testing stages of development that have not been partnered. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
anticipation of FDA approval of these products, we will need to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities.
These investments will increase if and when any of these products receive FDA approval. We cannot predict how quickly our lead products will progress through the regulatory approval process. As a
result, we may continue to lose money for several years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that we will achieve or sustain profitability in the future. Failure to achieve profitability could diminish our ability to sustain operations, pay dividends on our
securities, obtain additional required funds and make required payments on our present or future indebtedness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> If we cannot sell securities to raise necessary funds, we may be forced to limit our research, development and testing programs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will need to raise more capital from investors to advance our clinical and preclinical products and to fund our operations until we
receive final FDA approval and our products begin to generate revenues for us. However, based on our history of losses and the on-going uncertainty of the U.S. capital markets, we may have
difficulty raising sufficient capital on terms that are acceptable to us, or at all. As of December&nbsp;31, 2009, we had cash, cash equivalents and marketable securities of $82.5&nbsp;million,
which, at that time, we believed would support expected operations for more than 12&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continue to seek partnerships with pharmaceutical and biotech companies and with other organizations to support the clinical development of our programs, in addition to funded
research grants. This kind of funding is at the discretion of other organizations and companies which have limited funds and many companies compete with us for those funds. As a result, we may not
receive any research grants or funds from collaborators. If we are unable to raise the necessary funds, we may have to delay or discontinue the clinical development of programs, license out programs
earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or evaluate a sale of all or part of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
we begin generating revenue, we may seek funding through the sale of equity, or securities convertible into equity, and further dilution to the then existing stockholders may
result. If we raise additional capital through the incurrence of debt, our business may be affected by the amount of leverage it incurs, and its borrowings may subject it to restrictive covenants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I> The market price of our common stock has been and could remain volatile.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January
2009 through December 2009, the market price of our common stock has fluctuated from a high of $14.19 per share in the second quarter of 2009, to a low of $4.16 per share in the fourth quarter of
2009. Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=46,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=701960,FOLIO='20',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_de15102_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>competitors
could cause the market price of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock,
especially if those sales are made during a short period of time, those sales could adversely affect the market price of our common stock. In addition, in recent years, the stock market has
experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and
may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in
substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=47,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=972589,FOLIO='21',FILE='DISK132:[11ZAB2.11ZAB15102]DE15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg15102_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_dg15102_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our consolidated ratio of earnings to fixed charges for the years ended December&nbsp;31, 2009, 2008,
2007, 2006 and 2005. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Ratio of Earnings to Fixed Charges  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="30%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2009 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2008 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2007 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2006 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2005 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Due
to our loss from continuing operations for the years ended December&nbsp;31, 2009, 2008, 2007, 2006 and 2005 earnings were insufficient to cover fixed
charges by $36.9&nbsp;million, $48.8&nbsp;million, $15.5&nbsp;million, $18.8&nbsp;million, and $17.4&nbsp;million, respectively. For this reason, no ratios are provided. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_use_of_proceeds"> </A>
<A NAME="toc_dg15102_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>USE OF PROCEEDS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to
use the net proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, and the repayment, redemption or
refinancing of all or a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations until we receive FDA approval of our products and are able to
commercialize our products and to make substantial investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products.
Pending the application of the net proceeds, we expect to invest the proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase
and consist primarily of investments in money market mutual funds with commercial banks and financial institutions or other investment-grade securities. Such investments may include depositing such
net proceeds into, and maintaining cash balances with, financial institutions in excess of insured limits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_descriptions_of_securities_we_may_offer"> </A>
<A NAME="toc_dg15102_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTIONS OF SECURITIES WE MAY OFFER    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we may
offer and sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more of these
securities are offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These summary descriptions
and any summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in their entirety by
reference to our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions and
from which such summary descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the terms
described herein will be deemed superseded by the terms set forth in that prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable
prospectus supplement. Each sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the
securities only in registered form, without coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or
quoted on a securities exchange or quotation system, the applicable prospectus supplement will say so. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=325763,FOLIO='22',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_description_of_common_stock"> </A>
<A NAME="toc_dg15102_4"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF COMMON STOCK    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2010 we are authorized to issue up to 297,000,000 shares of common stock, $.001 par value per share. As of
March&nbsp;31, 2010, approximately 31,759,718 shares of common stock were outstanding. All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is
listed on the NASDAQ Global Select Market System under the symbol "CLDX". </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Dividends  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of
shares of our common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Voting  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including
the election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Rights Upon Liquidation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled
to share equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Miscellaneous  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any
class, whether now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be
issued, sold or offered for sale by Celldex. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> Anti-Takeover Provisions  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate, as well as our
shareholder rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders
receiving a substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring
control of our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a
single director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to our shareholder rights agreement (referred to in this prospectus as the rights agreement) a dividend of one Preferred Stock Purchase Right (referred to in this prospectus as
a right) for each share of common stock of Celldex was declared for each outstanding share of common stock of Celldex on November&nbsp;11, 2004. Each share of common stock of Celldex issued after
such date is also issued with a right. Each right entitles the registered holder to purchase from Celldex a unit consisting of one one-ten thousandth of a share of Celldex
Series&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock, at a cash exercise price of $35 per unit, subject to adjustment as specified in the rights agreement. We describe
the rights more completely in the rights agreement itself, which is contained in Exhibit&nbsp;4.1 to our Registration Statement on Form&nbsp;8-A filed on November&nbsp;8, 2004. The
summary of the provisions of the rights agreement is qualified in its entirety by reference to that agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare
Trust Company, N.A. is presently the transfer agent and registrar for our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=322759,FOLIO='23',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_description_of_preferred_stock"> </A>
<A NAME="toc_dg15102_5"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF PREFERRED STOCK    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2009, the Company had authorized preferred stock comprised of 3,000,000 shares of Class&nbsp;C Preferred Stock
of which 350,000 shares has been designated as Class&nbsp;C-1&nbsp;Junior Participating Cumulative, the terms of which are to be determined by our Board of Directors. As of
March&nbsp;31, 2010, there was no preferred stock outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Class&nbsp;C Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the general terms and provisions of our Class&nbsp;C Preferred Stock. The applicable prospectus supplement
will describe the specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares
of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class&nbsp;C Preferred Stock In general, our third
restated certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there
are sufficient authorized shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each series of our Class&nbsp;C Preferred Stock, our board of directors has the authority to fix the following terms: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation of the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of shares within the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below
under "Description of Depositary Shares";  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the shares are redeemable, the redemption price and the terms of redemption;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amount payable to you for each share you own if we dissolve or liquidate;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms
and conditions;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any restrictions on issuance of shares in the same series or any other series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>voting rights applicable to the series of preferred stock; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other rights, priorities, preferences, restrictions or limitations of such series. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rights with respect to any shares of our Class&nbsp;C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class&nbsp;C Preferred Stock that
we issue in accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by
issuing a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate
a business combination transaction by issuing a series of preferred stock having sufficient voting rights to provide </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=613043,FOLIO='24',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>a
required percentage vote of the stockholders. Additionally, under certain circumstances, our issuance of preferred stock could adversely affect the voting power of the holders of our common stock.
Although our board of directors is required to make any determination to issue any preferred stock based on its judgment as to the best interests of our stockholders, our board of directors could act
in a manner that would discourage an acquisition attempt or other transaction that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might
receive a premium for their stock over prevailing market prices of such stock. Our board of directors does not at present intend to seek stockholder approval prior to any issuance of currently
authorized stock, unless otherwise required by law or applicable stock exchange requirements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Terms of the Preferred Stock That We May Offer and Sell to You  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable
prospectus supplement provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus supplement, which will contain additional information
and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock, we will further
amend our third restated certificate of incorporation, as amended, designating the stock of that series and the terms of that series. We will file&nbsp;a copy of the certificate of designation that
contains the terms of each new series of preferred stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number of shares included
in a designated series and fix the designation, powers, privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions. You
should refer to the applicable certificate of designation as well as our third restated certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in
the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights,
conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred
stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of
directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate action. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where
applicable: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation, stated value and liquidation preference of such preferred stock;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the number of shares within the series;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the offering price;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether
such dividends shall be cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether interests in the shares of preferred stock will be represented by depository shares as more fully described below
under "Description of Depositary Shares");  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any redemption or sinking fund provisions;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or
winding-up; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=495654,FOLIO='25',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our
stock of any other class or classes, or other series of the same class;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series
redeemed, purchased or otherwise reacquired, or surrendered to us on conversion or exchange;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the
purchase, redemption or other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon
liquidation;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of
any additional stock ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges,
limitations and restrictions of such preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our
third restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus
supplement, each series of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the
holders of our preferred stock will be subordinate to that of our general creditors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_description_of_warrants"> </A>
<A NAME="toc_dg15102_6"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF WARRANTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides
otherwise. This summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement.
These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the
warrant agreement. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We
may issue the warrants under warrant
agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act solely as our agent in
connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being delivered: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the title of the warrants; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=230998,FOLIO='26',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and
conditions relating to the exercise of such warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of
warrants issued with each such security;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the price or prices at which the warrants will be issued;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the aggregate number of warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the
exercise price of the warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the price or prices at which the securities purchasable upon exercise of the warrants may be purchased; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will
be separately transferable;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the
warrants;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the date on which the right to exercise the warrants shall commence and the date on which the right shall expire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>if applicable, the maximum or minimum number of warrants which may be exercised at any time;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the identity of the warrant agent;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any mandatory or optional redemption provision;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the warrants are to be issued in registered or bearer form;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the warrants are extendible and the period or periods of such extendibility;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>information with respect to book-entry procedures, if any; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any other terms of the warrants. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive
dividends, if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Exercise of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities
at the exercise price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business
on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set
forth in the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust
office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants
represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=53,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=697485,FOLIO='27',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<A NAME="page_dg15102_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Enforceability of Rights of Holders of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or
responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive
the securities purchasable upon exercise of, that holder's warrant(s). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> Modification of the Warrant Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the
agreement in the following circumstances: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to cure any ambiguity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to correct or supplement any provision which may be defective or inconsistent with any other provisions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and
which do not adversely affect the interests of the warrant holders. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15102_description_of_depositary_shares"> </A>
<A NAME="toc_dg15102_7"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF DEPOSITARY SHARES    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides
otherwise. This summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt
applicable to any depositary shares. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should
read the depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the
information below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of
common stock or preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will
be issued to the public. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us,
and the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least
$50&nbsp;million. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred
stock represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the depositary share, including dividend, voting,
redemption and liquidation rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the
fractional shares of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=54,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=613861,FOLIO='28',FILE='DISK132:[11ZAB2.11ZAB15102]DG15102A.;4',USER='LPALLES',CD=';4-JAN-2011;12:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di15102_1_29"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A HREF="#bg15102a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_description_of_units"> </A>
<A NAME="toc_di15102_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>DESCRIPTION OF UNITS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security.
The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The
applicable prospectus supplement may describe: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the designation and terms of the units and of the securities comprising the units, including whether and under what
circumstances those securities may be held or transferred separately;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising
the units;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the terms of the unit agreement governing the units;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>United States federal income tax considerations relevant to the units; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>whether the units will be issued in fully registered global form. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their
entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. The forms of the unit
agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to
you. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_plan_of_distribution"> </A>
<A NAME="toc_di15102_2"> </A>
<BR></FONT><FONT SIZE=2><B><I>PLAN OF DISTRIBUTION    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public,
negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities,
including without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute
securities from time to time in one or more transactions: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at a fixed price or prices, which may be changed;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at market prices prevailing at the time of sale;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at prices related to such prevailing market prices;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at varying prices determined at the time of sale; or  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>at negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus supplement or supplements will describe the terms of the offering of the securities, including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the name or names of the underwriters, dealers or agents participating in the offering, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive
from the offering;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any over-allotment options under which underwriters may purchase additional securities from us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any agency fees or underwriting discounts or commissions and other items constituting agents' or underwriters'
compensation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=928337,FOLIO='29',FILE='DISK132:[11ZAB2.11ZAB15102]DI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:14' -->
<A NAME="page_di15102_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any public offering price;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any discounts or concessions allowed or reallowed or paid to dealers; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any securities exchange or market on which the securities may be listed. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any
public offering price and any discounts or commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material
relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any
commissions and other compensation we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the
period of its appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with
respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary
course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is
currently no market for any of the offered securities, other than our common stock which is listed on the on the NASDAQ Capital Market. We have no current plans for listing of the debt securities,
preferred stock, warrants or subscription rights on any securities exchange or quotation system; any such listing with respect to any particular debt securities, preferred stock, warrants or
subscription rights will be described in the applicable prospectus supplement or other offering materials, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act.
Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those
activities may cause the price of the securities to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=100391,FOLIO='30',FILE='DISK132:[11ZAB2.11ZAB15102]DI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:14' -->
<A NAME="page_di15102_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<BR>

<P style="font-family:times;"><FONT SIZE=2>be
higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
agents and underwriters who are qualified market makers on the NASDAQ Capital Market may engage in passive market making transactions in the securities on the NASDAQ Capital Market
in accordance with Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits
are exceeded. Passive market
making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum compensation to be received by any FINRA member or independent broker dealer may not
exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_di15102_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" into this prospectus the information we have filed with the SEC, which means that we
can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by
reference into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009, filed on March&nbsp;12,
2010, as amended by Amendment No.&nbsp;1 to our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2009 filed on March&nbsp;31, 2010.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our Current Reports on Form&nbsp;8-K filed with the Commission on January&nbsp;8, 2010, January&nbsp;25,
2010, February&nbsp;16, 2010, March&nbsp;4, 2010 and March&nbsp;30, 2010 (in each case except to the extent furnished but not filed).  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The description of our Common Stock contained in our registration statement on Form&nbsp;8-A, filed with the
Commission on September&nbsp;22, 1986 under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended, and any amendments or reports filed for the purpose of updating such description. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The description of the rights to purchase our Series&nbsp;C-1&nbsp;Junior Participating Cumulative
Preferred Stock contained in our registration statement on Form&nbsp;S-4, filed with the SEC on December&nbsp;21, 2007, our registration statement on Form&nbsp;8-A filed
with the SEC on November&nbsp;8, 2004, our registration statement on Form&nbsp;8-A/A filed with the SEC on October&nbsp;22, 2007, our registration statement on
Form&nbsp;8-A/A filed with the SEC on March&nbsp;7, 2008, and any amendment or report filed with the SEC for the purposes of updating such descriptions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (a)&nbsp;after the initial filing date of the registration
statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a
post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold.
The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this
prospectus, commencing on the date on which the document is filed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=388263,FOLIO='31',FILE='DISK132:[11ZAB2.11ZAB15102]DI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:14' -->
<A NAME="page_di15102_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we incorporate by reference the documents listed below made by CuraGen with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CuraGen's Annual Report on Form&nbsp;10-K for the year Fiscal year ended December&nbsp;31, 2008, filed on
March&nbsp;10, 2009 as amended by Amendment No.&nbsp;1 to CuraGen's Annual Report on Form&nbsp;10-K for the Fiscal Year ended December&nbsp;31, 2008 filed on April&nbsp;30, 2009
and Amendment No.&nbsp;2 to CuraGen's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2008 filed on June&nbsp;19, 2009.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CuraGen's Quarterly Report on Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2009, filed
November&nbsp;6, 2009. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by
reference other than exhibits to those documents. Requests should be addressed to: 119 Fourth Avenue, Needham, Massachusetts 02494, Attention: Corporate Secretary (telephone number
(781)&nbsp;433-0771). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone to provide you with different information. You should not
assume that the information in this prospectus or the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Celldex Therapeutics,&nbsp;Inc.</B></FONT><FONT SIZE=2><BR>
Attention: Investor Relations<BR>
119 Fourth Avenue<BR>
Needham, Massachusetts 02494<BR>
telephone number (781)&nbsp;433-0771 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_legal_matters"> </A>
<A NAME="toc_di15102_4"> </A>
<BR></FONT><FONT SIZE=2><B><I>LEGAL MATTERS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon
for us by Lowenstein Sandler PC, Roseland, New Jersey. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the
underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_experts"> </A>
<A NAME="toc_di15102_5"> </A>
<BR></FONT><FONT SIZE=2><B><I>EXPERTS    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of Celldex Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2009 and 2008 and for the years ended
December&nbsp;31, 2009 and 2008 and management's assessment of the effectiveness of internal control over financial reporting (which is included in Management's Report on Internal Control over
Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form&nbsp;10-K of Celldex Therapeutics,&nbsp;Inc. for the year ended December&nbsp;31, 2009
have been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst
&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Celldex Therapeutics,&nbsp;Inc. included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2007, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements as of
December&nbsp;31, 2007 are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=138798,FOLIO='32',FILE='DISK132:[11ZAB2.11ZAB15102]DI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:14' -->
<A NAME="page_di15102_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
HREF="#bg15102a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements of CuraGen Corporation, incorporated in this prospectus by reference from CuraGen Corporation's Annual Report on Form&nbsp;10-K for
the year ended December&nbsp;31, 2008, as amended by Amendments No.&nbsp;1 and 2 to CuraGen's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2008 and the
effectiveness of CuraGen Corporation's internal control over financial reporting, have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, an independent registered public accounting firm, as stated
in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in
accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di15102_where_you_can_find_more_information"> </A>
<A NAME="toc_di15102_6"> </A>
<BR></FONT><FONT SIZE=2><B><I>WHERE YOU CAN FIND MORE INFORMATION    <BR>    </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act with
respect to the securities being offered under this prospectus. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of
certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete,
and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated
by reference in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and special reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at </FONT> <FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex
Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room, located at 100&nbsp;F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. We make available free of
charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports
on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or
furnished to the SEC. Our website address is </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. Please note that our website address is provided as an inactive textual
reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such
information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained or incorporated by reference in this prospectus. No one has been authorized to provide you with different information. If anyone
provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus, as well as information we filed with the SEC and incorporated by reference, is accurate as of the date of those documents only. Our
business, financial condition and results of operations described in those documents may have changed since those dates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>
PROSPECTUS<BR>
April&nbsp;22, 2010</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=59,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=273059,FOLIO='33',FILE='DISK132:[11ZAB2.11ZAB15102]DI15102A.;5',USER='LPALLES',CD=';4-JAN-2011;12:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2>
<A HREF="#bg15101a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,000,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g148431.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="63">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="27%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="27%" ALIGN="CENTER" >


<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> Prospectus Supplement  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="27%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="27%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>
<IMG SRC="g1023782.jpg" ALT="GRAPHIC" WIDTH="171" HEIGHT="58">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>January&nbsp;6, 2011  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2201537",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=22202,FOLIO='blank',FILE='DISK131:[11ZAB1.11ZAB15101]HO15101A.;6',USER='HYUNG',CD=';4-JAN-2011;23:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g148431.jpg
<DESCRIPTION>G148431.JPG
<TEXT>
begin 644 g148431.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_``!$(`#\!!0,!(@`"$0$#$0'_Q``?```"`@("`P$````````````)
M"@`(!@<%"P$"!`/_Q`!($``!!`(!`@0$`P`,#`<!```$`@,%!@$'"`D1`!(3
M%`H5%B$7,4$8&B(C)#A187%XM_`9)B<R6')U@9&4H=$I,S0U-CK60O_$`!T!
M``(#``,!`0````````````4&!`<(``(#"0'_Q``T$0`"`P`"`00!`@0$!04`
M```"`P$$!081$@`'$R$4%2((,3)!%B,S420F87&S-39"=<'_V@`,`P$``A$#
M$0`_`'^/'JI248SE6<8QC&<YSG^3'WSG^C&/OG/Z8^^?MX]LY[?W_P"O]&/S
MS_-XZ^7K8=7'F5MC=^S^*T?$;-XDZ9HLB95)K5YCOTQLW9XB\YR/9]E3T(0Z
MXNHVF/\`+(5FI5&?,I,K736#965N#I"5Q[SP#@6I[@[)9.;8J5`KI_*O6[;(
MZKUO,5R:JPE#[39(H$%JB`@I'YW(`H/TI<RYAG\+RXTKR;%DFL^"K6KA/;G^
M/EXFXHE2`B/LC.9*8[^-;"B1]-J\D>LSTXN+AYD!L'DG4[%<0'7!RZ1J5B0V
MY9P2F5+0^)+,T0>8B:^4PM&6W1K#,1+Z'<^FIO"L*PFC:?B>^FMF2P"H'DD@
M3)'H_.E:=`S'8;]53>#,C(O*YOVV48P_AO$3DWTEX3D/#^%-)Z]!.,)3AM&$
MH;3_`)K:$X0VG_50G&$)_P!V,>)XU=0_AIX0BN`7]'?OVO'_`#'A9J4TR77W
M*JXTW$L>_N!8]\_?V4Q]>LZ7/?GE3GD5.CDTZ\%^Q1)?89X_[-:;Q@BG^\K6
MJ.OJ![^Y[17C?UE^G%RB.`@=?<E:C7[E(J;9%H^V&9'4EG++><PVR#%LWL:'
MB)\UY><(:%KLS+O+6I*$HRI6,9*%A6%8[XSW_P"F?YOMG[_?\\?RX^_Y>.FH
M5C"DY0O"5HS^:%IPM"O]9"L92K_?C/ADWHA]6KF9K;>VKN)TC%;'Y9:=V#+`
MU2&UZDOY_L;5`BWFL%6ZB6>?(1Z-(JD?ZDA:*I<)X&FQD&.Z9#S%3)9].4K[
MGO\`#I&1G7-GBFNRRB@AUNUF[+*RG172$L:=;1`:U8B6$&7PV4HB0&>K),\0
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M@$<`(RT*$"*TT,(,TVPPVAM"4XO._./[34<NA&%E[W/M'/K:NI;WJWY^?QM-
MR/EJ9U+-.12S1!<0RQ9=W*CZD/E2X5JJ:G&G[BV]&W.M?R.'TKCL[/K93?Q+
MFVRM,#9NVKH^3!I$SL$H`8@QB?+P8!&:8\E\/7U4Y?YC9)7J+5.1NYLDJ2>R
M5=N0#S4B4OR/N2!EF6`DML]1:?LG$`0E7E0^HI&<Y:1@5XW'\09TB"!KSO"P
MN\H>.<+("HL%@L,@QNG6Z0?5'CVVY:]MPU?W5JC).2&!(J8L+8E<Q)O#I<'F
M'E*!)>'\<;,0\58(J3@IR,CYF&FHXV)EXB6#'D8N5BI(9T.0C),`MMT4Z./$
M>>%-"):<')'=<9>;4A><9$H]W]2TP$<GX]Q7DN24P#J+\*A1<"2Z$_P+M%*6
MT['A'2W^#I`H@O&9B)B>SVSSJP&[`V-_#T8CR7;3J6;*S8,R0_F5K)F%E4E_
M6OR7Y#,QWU,Q(^.F[U*](=2341=[UNV74+[4'@(K:^HK`:(79:'-'#>N*0P6
M,EAJR4V:4V7],V\0,-B3R$<"?'Q$Y'2,4*1GPFQQLX,\G^F_UR7">/6B=PS/
M"/9<XY4).XP-5FY?7L!J?;4`FP"P,W9,NOM,CZ7V:'&,HD)$ATT.$A6'2W'/
MF9*B7$9R>A:Q"2EDLTO%UZOP4:9,3LY-R`D3#0L3'#K+D926E#WAP8Z-CQ6G
M233C"&111VG'WW6VD*5A=Y]AX>3LU6\6N1=PMS-I[&8F7A9N9XW8+SRKW@;#
M&W4:,CX-F7?&:H83&P9D<X?K:VCEO7OU_P`;7R;MG,OMA1)K7"J^/CH5O*("
M46`*"\@Z7YBR0$%R`QRWB>%9.2_Q-6NHO83^H^#/'FV\JK,LYV*C+@81.UVL
M6*2%+6T_]!4NN5NR['O48XRWYAI90-5&*]5LH%LZ/4R21J"0ZWO65HT<U>=D
M])J5`UPA!1IAR-8\DZZ\/'#O)QEXR:)$LJ(AMEM6,++E:RRP1W]TTVV.E6,$
MJ_M#SER*[WY]+,*V,'4J;&SDY=ZR)1V/A2NW%60(NIB`<M1Q,3W$1$S$)WN1
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MV^K3R!W#L#<EC@.035>A)O84^_8)**@\ZNHDIF)!)(2E;`&9(\T[(Z>Z?<E/
M._YSBN]5.FGRZY1;,ZZ/,K1.PM_;3N>F:9)\O6JGK"Q6@F0I==:J&Z*S"U5N
M(AG$89$37H@HB-B?(K.1`WG&4YRE>>^P?A1OXH')'^LTS_8_KGQ33I-__8HY
MX?[7YP?V]U'Q=>IEY@<A]_%AG417GX(LH+&I7@*+);2B64PA?C6/HBCR3`%^
MZ?O[]55GZ.@6/[/&5VT1WM0AN%+V25H?!D^-@I+MP]__`!.2C^W741Z=K\3Q
MJ+>N^-2\:M76O<V[KO#:^UQ2X]<A.V*:>4EM'VRD6.C@V$/2$U.RI'D!A("(
M%-F)F0=9!C0B2'$H\*^7_P")>V7M>_2&ONGWP2OV\70EO*$F+:S<)FQR@N6'
MDCR.=5:D@Y^2@HY9#2GQW)VYL%F"-K9>$BRU*0/2?&^#\GY8%AV+F$ZG4GJW
MHV7UJ&;6+J)\&WKK45_DB"$I2##;`D)2N!F)]6MN<LP>.DE6I>%5JS'=>DE3
MK=UXQ,QY!5JK:V`[@HAAB"YD2&#[B8AN#PLY\2WR:Y#<9])<9YOCWNC8NF)B
MS[5OD389/7=B(KIDS&`ZX?D`@9%X=*E$BBGXP8PTKMALC&'<?NL)SBN[/Q`/
M4-T$>U.\W.EU<J1J];S#!MHKE<V]K9Z);>;'>60W)[*A[)295]ME]+B`#K%6
M$N+6D5R2&=;>4BN_Q"','0_.'@UPUWCQ[MZ;143=X;*AYF/,%7%VJDV@74N"
M9"H7>`=6Z_`V,%DH8G(JGB0Y&.*"F84^3A3PI`BS>!>W6YB\^XDW>RJ5[$NW
M[%?\RM8S]S':W]-ML&N]M1MJNMO[?-:K4+(Y"25!>$S"-RSFV1J\1Y&O)OV*
MNK6I*=%:PBUFZ`!%VL,N2NPM+&+CR\28B3@.^CD>XB6\>)EAG;;Q8XU6JT2Y
M\_9;+H#35@L,[*/Y)DYJ<FM;UJ2EI:1)5C"B#I*0*(,+?5C&72'W',XQE7;Q
M8+Q67A7]N'/$_O\`Z-.A_P"RJI^!?]1/KX\7."UPEM-U>!F>1F^X%]`5FI%,
MF0(&I4.1=;0IN'O.P2Q9=@6RYR^/ZE3K,'9IP%2LC3K<$4X.R]5E3CFSR3D%
MW*X_F/T+<V[A17K``@E(6"&6.:<KKU:X20!\KF*2)$`>4$0Q+X_<S,/$IZ.S
M?53K_BU8ESR(C:TT!/@I80;GN/\`<7QJ!C)B"+QZB9@[7B>%`X[K=]9F]Q>;
MKK/I-2DA076AB0Y!>K^2ED46*42XAD@&5&&K.)9AYKR-X?C(`AII25%N*R,\
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MPA9J)%O@Y#;0=7FG1XJ%3%-3Z5X^FK`ETV&F7GXQ#+R!IB/,=JBW?J46(5<;
M^.=ELI3\@,@";$Q'QDR`E:SF9^A883/4]=]3T:V>5\?X_8RJNSHAGLV[,5,Q
MCT6OQ+%HI"!05X$'2KM/S&5A:L)ED=R'E`E,&+\3Q,9QG[X_O_VSC]<?GC/@
M>O4;ZCFE^F]I=G9NRV2;7;[.>Y!ZLU-"2#$?9]C3HV!WI)L4T@4X>#K]?!?0
M?9+1("/`1;;@0+31LS*Q4:8:S,R_L7ZN7EU77;]UPHJU4#Y,:POY1'<P(B,1
M)L89"M2Q)C#$!(H+7[]/,IV+]^PNK3JK)MBPV>@6`_WGJ)(BF9@0`8(S.1`!
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MY091R3Y97?DGM)S=O(#<FVW%H6C86P9^QA^EDG++<6\ZV%##L8-;:+2P-#`@
M#LH)::>0VTE+C;:L>1.;<3N7.W.'FRF-@ZOE$N!'9##N]'E''55>^P(Q&'<Q
MDPPWA:@Y$=&7OD=F";S+0+[SF6?=1Y!\8=5?'?<[8XWR@M:G<?76J\;*5BM,
M?-3`)E2R`>I!]=R1B+=5@DMXFR9$O-BVXDJ>_1/Y9R:ARU`[O`-S4L)16\(8
M_'I*.*M*Y0\?&6**LE-BW7&1.;!'=IFNQ+5V@><JN)V\N&&X[%H_?U-*JEQ@
MEJ?!-:P055KI7UNJ:C[E0[`Z*(Q9:I*^7/MI!EIDL$I+\/.@1,Z$?%C5P\=F
M;?=?\)>NAQ1<B)T7`=I@6<K!DV$12-S\;MAR0R59<"(<;<:+AY=0"$DC*]>F
M;'@1L)?0S("-KA$EA.D#R))ZDKO3;?G:B'=V5/V1S9ZDF/4S\(6X7ZG9V:Q%
M)<1+D.$P2V1FZ=A])S=N<56WY9L-A^?1]/\`VQ][\#FV%8M:EBMF:>3FLTM.
M1DIHV<^L(P_3HS'F?QB1##Z<P5A#2A80X9@HG<H]O6TVY>CQ2Q'(>.<B>E6)
M=JF#3^:U,PFG8(?$?DF1,8;,`/:V"\4-`UQ3/B9Q%WKS7W)!:/X_T]ZU6V52
M@^7D'W%!5>CU=LM@22NEYG<MN,P59BE$(2Z]ELB1E#%,P]?CI:;+$CWNP2XH
M\0N&W0YXRS=WME@"FMDSD8,+LG<!\:,UL';%@:R[(1NN];UITXA^,K[17?,#
M2XPY3?E'5:+K*E$"ES(63U*H\)^AAQ0%KE:`?,GI]W+SRUJCBMQ<AMBB@H0[
M*3!N4MMAPT9A3:5+0VQ3==PCZ!8T-P\UL>:5VY4<LMO<OMDE;%VK,=VV/7%J
M%*BWR\4^@PSV6_-%5L$EQ6<OE899<FYXI.9>?*;0\:XT*R#'@Y(]^?XB+/(#
M;A8DLJXP'VFC)2#[Y#,2J]L2$]@B)Z;4S1+KOQ:\C8*S08U-;CWL=0CN*N_[
MF7JO::TS\E'CJGA$PVQ(S!"4Q,3`P06K@_M5-:H;'M8]Z>O53M/+'E+LK5E^
M@HBI5JVPA%BT5!A90](0C%.PK,[6I^6QGO89Z;@2DVA\X=`P0I$++!1PN`$,
MON%LY&R4C#\?MY2\.IU,M%:=VA)1>62&Q'L2(-%GR@LM%.X4T,Y@EIK*"'4J
M;97C#BTY2G./"+/"VZGZ\Y<<;+='97Z\?NF@`/-MN9:41&V:=&J4P+E?F3C"
M28B?.95A>?)G*L>?"D_N<O[3D.!8826@)1GW$9,QI\/(L95C'K1\D*]'FM^;
MMG&,N"OO)[]L]LJ_+/Y>*1X+LOOH)M\ILMIZ(F<E$1\B3('P$Q$0'43\JQ&.
MA%<`/41$>K$]AN:[/..([:]RZRYK9VM:5^<R!$SJZ2HMUXGP`5C\#SMI2M8P
M":RZZ0`06,>DS?A(X>.=E.;E@<9PN7%K_&^''*RK/F1&GN;:DBVL([]L^N8$
M*\M?;OG+2<9SG&,=G2?"$_1-V`YTX.K5NWAEN<A57`V3(6'CV*;,$H#"5?J3
M:'K!I&4=>4G+;XNPJX:;&UTA*D-'&W>OX;7Y2\8P^OC.,X[X_P"W_'&?OC./
MUQG[XS]L^-%^^J&3[@7-89EF?OYF)J95D>Y58I3E5*GFL^Y&8AU9LS`S]00E
M,=&,RY>TCE_X.KYT_LN8^AJT-!!=0Q%F-"Q8\##^J.EV%C$S]3XS$3U'4>?$
M\3QXSGMC.<_I^GZYS^F,=^WWSG[8Q^N<]O%.^K-]>N<MX5COE&%?;MWRG"OY
MNW?[_P!'A4[XHCEA<:7J/1_#C7AD@,;R)EYNU[&:C'W1B9VCTF0A8>M4-[T_
ML3%W.^3HILF/YD8?14!0"4$`R!3"]:7'GYRCY8]>>E<9.+?("\Q'&/7>PJO6
M]@0-*E(9JFVNOZ3#*MN^IHTY,:>Z^#,SC9NMVSAI%#<A@6-:`6VHYIU5>OBF
MZ<MCE=PSO-K>E`==6/54]3I"1CL>5^/Q5=J`S-R(C7B$OA(E6JU=@31L.BJQ
MZ@+"R$%L(PTU?WMSP></W%X(O?93>[3Q7\KJYHBUCZI#0NV<U=U+%JZMK97F
MX*5D715Q@B[[CU3O-N5_JO"N6'CC86JCJ*P'7I(%I>)7*R+IUG"1Q\!"[\8V
ME$1(OF1_EWZ8]Z8/3ITCT\=#5FL0\779'>ED@HN1WAM0K,<39['<BPA7YFOQ
MTPOL9&4*M2'JQ59K83@X.!Q,S$DT9/24E($$VS)1F>_\/#^_;OG!H^,Y[?EW
MSA[&?M^GW^WA7&-^%JX@S0`<O$<K>49\5*"CR,6<-):H('-C3F4%@%L$(H"4
M/M$B/,O-O(2A#J%X6E*4JQC'V_M5?BE_I1<JO^<U7_\`@?"SK4^#;>C;U-7W
M/V+>A=<;K+W<'N29,*?L8B=V?C6N/V+4/0*6`K6(@(QZ-9MKEV51JY^=P#+K
M4ZJ@4A2N65X&`&!CRF8R/WF?V9L+LF',F<R4E/K57Q&W3NUB#K%/4,T/'`:_
MVQKVYU7\:GJ.@6'^L86QST?$5[:!"8AQA0VPZ+<WJ]E5E$9;D)6(DW29@I\N
MOQ1+1&:=RDEN9'00VEOJSDL%WFQ<'>1->V,^PQD9).PZ#0[S1[A(Y&PA#(WS
MR7@7I](XW<9E$LEIGLVC"4T&OWPS?`W6,`JR[0YM;VU_5E&"1BYZ^W'1M4K^
M3SU*2#'N2ECI\?&9+-<;6D01;^7B5MJPRVM2,]B!@\5M,\/>BURUU+H';DGN
M_5CO'7EQ<J[L.1GJA96I1=IH]M(E1HJ9HHHE8+C(^5%+%;S'MKR@I)B"G5E)
M=[,VCK\;M\9X5BU>0:7)M/#YE2C,U+N!9RHKXEKX_P`C)_(=:NPV$VE(<D9?
M!`F!2"A4@9]`Z6;NU]OE6I9QL_!HZO&+4WLZIL)T"=IH$_BTI2JO5E7R()B6
M3\,^;))A,DSF(I'\*-_%`Y(_UFF?[']<^*:=)O[?$4<\/]K\X?[>ZEXN7\*-
M_%`Y(_UFF?[']<^*9])W'?XB;GEC^66YPX_X[ZJ6/#3K?^Y?XA_[?\O!_P":
MCZ7<W_T7V4_^V+_Q,]>W7;V!M'G5U.>.W2_UW/.0]6K,QKP*39QEXN+3M+;$
M;FQ35]GP`T8R>/K#4)(Y44POU7`4R-K\CS&95U33:/$WB-HOA;IRMZ5T)3`*
MK6(407,K*)9979[S8$CH:D;G>IQ#31=AM$RZE9)996<#`H6W%PPD;#!@QXZB
MNV9`+1/Q4-4M6Q'&UU^\[-UPJ`DIY>&Q&$;;XW,ZOJ10C[SRFVV(R\O?)07%
MK;0R2RXGTV_+VR\"G_-3^GVQC./Y,X^V<?[L_;Q7_N78?G<7]L^.T#)."WAN
M?R!JTS()O;>HQS-!]CQZA[JYB,+AOE-:'F(>/G/;IP1*KV_SK;N`+-=7);F.
MLV]&VKE404%)29F)^);A(I*0\8=*X/\`</77Q2<7&S,<=$2X`<G%28A,?)1D
M@,R;'2`!C*QRPC@2D.B&!E,..,DBDLNL/M.+;=;6A2L9Z^'XAGIU53A3MRI;
M-T/&HI_'GD>Y8)$C6,*X2-4Z%N:F1><3"8.'P^L("%LU:GW)>N@MMX17WT6Z
M%B$AP"@(X7L+?"D/Q8^Q:V-HOBOJ91C"[?.;5O&QV0$/(42-5ZCKZ0JAAQ`^
M$J<:8,FKQ'AANK4VEYT0U+>'<CO99\_8K7U*'N)BTJ+&E4UBL5=*I$D275UT
M[%@7FO[&&4V)&PMW4&$"804`U@E[>[6;GW.%Z=JT"QLYT(L4K/T+5N*RA1)$
M_HI79`Y4Q7<@<R!2,FL)$EG(SE?*\,.B+3-W54EH78(W$CCS2-8O.*[+%V%L
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M37QJ^]&1PZOHT,^YHAFH59L6%UW:0$ZM:![EB()`85$K(0=!B:OMWG$E&8[?
MP\/[=^V<FCYSCO\`GVSE[.?O^OW^_@8?5'Z=6E^H9Q_M-;D8VN1N^:Q!24KH
M[:8[<>W9J_;P!""HNM2,JVM!LE1;45C$+8J^:Z2"TV<B=CAAYZ*C3&1=?M5?
MBE_I1<JO^<U7_P#@?'SF?"Q\1X\0D\_E9RB"""'?+,,+DM3#"B"C-+?())(>
MHB&6&&&6UO//.K0VTTA3BU)0G.<).33X-B:5/5RO<_7J7Z3UOK/5P>W!"P"B
M?$HC=Z8MD=K:HHD&KDUF)`4Q+5I6>7ZU&SG:'`,NQ3MI)+U,Y77(9`XB)*)+
M'GP,)GR6R.B68B8R)#W'X_"\\L+3?]$[DXBWZ4?)D^-T_#3VNPI)3[DE%:ZO
MY4XQ,5-MYQU:5Q],O\)+)"'PVWB,$LXT:/GV(P3`Q+>J)TXXOEM3G-GZR`!C
M>1-(AULQZE9P,)M&L`H)*Q0YMWS(89F6777'*58"<=@#77(61=1#2/N8O4'2
M8Z;/#;AKL/;6R>*7+:3Y'OVRDU^E7:)3>=,WB*K[&)YZR5Z5(?UC%L2$9(%K
M#EAP42)B0Y`19SB!B'A&WABT<A^0>IN+6GKOO3=UJ$I^N*%%_,IR5)0L@A]Q
MYYL.,AH>.8PHN9L$])/C1$#"A-N%RDF6.*RG&%+<;7/=-&'R_F>T.%2M.I;M
MBH::94'5;A:=JO7BQ**9#\P/?H$UZH@2(S='7D)^/J/G\6KZ_ML'&^<C5L55
M4["GV!N*>-6O48TJ5Q%^)(%6,](A`/\`J`E,BP27+!,#W"#JWS5"T]L?4?)2
MI[(OFZ]&5"T2&OH6&B7I#:FX4T<4MR0U.9#G8%(SMFM,`/MI<.6X=88&.D"R
M&#+#!FHF@_<,.+'(3K\<QK)S1Y?.2$5Q8ILVW#IB(DB0C8*9BX=]V0KW'O49
M+C&?\6(A)#16V;J,XW*FOR)7<INVV1#M=Y.J;/W!U?+[RFY+:8XU&ZKLVC)6
M'NM>L.MWR1,7.JL%,*AZU:YS,DPH[E558R/'OT/-T<<8>T5IHV`/`C9BOT.:
MMK`_2&YYT;=.O(OCC9(JI4#<%`C)$N(B*O!1M3K>RZY@MV3FK;"PL4*#%`77
M$K(G2NQ(0,5A9\F:7<0V,LR$N-$1,#DO(/9>YR+@VUF5Z_.+E>G6Q^6?F+LM
MIXUJJ-BU2K_"3$IV)!E99.AHO7,'!01A7:^H>)Z;M?9X]PCG&Y8T,*M-JQP_
M2=796J<[51?"*5?1<_HRT,V`8ME9DE^;$)B2:;56M`S-=KL#48"%JM6AHJNU
MJN10$'7X"#CQ8J%A(6*%:"C(F)C`FF0X^-C@V61`@A6FV!AVFVFD)0G&/$\<
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M5[_$3_QJOJSU\_Q7?E_J^?\`_GZ*]'R]^_Y?IV[]^W\WC8_\/>1^5P[?L^/?
MS\0Y?3[^_N2MHF([_P!^O]NY]:S]M;8J]KO;-<^,2',H;,]QWU_B#=B>_P#I
M_P!_K_OUUZ(CUS[$FURG%*<PI+BWZMNH9;N.V<J]K;*,UA.58^_EQA*?W/?M
MWQC/;OCOX`=X+MU.[%]4:]XAR_J>IYQ^1HWF[]__`$UWH*>W?OG\O-]O`B?&
M5>?(_%YAO5NNH1:6J(^_KPJUQZ^_^L3ZSO[XG#/=+E+(ZZ,L8OK[_JX]DS_^
M]^K"<2JF9>>4G'.I@,-$D3.[M9(RT^WAT?(D?;8N:DW"&\_98X\5&'$OI_5I
ME>.V?RSV$:?R^WY9SG./Z%9SG'Y_T^%-.ACQBDKUN^>Y+3T:ZBF:<`D*[4BR
M!\^VE]F6F-4$7D);B<M/_2%1-,=.4WW4-(6:'PG*7F7,(;,\./`Z3*^4ZRR)
M'\VQ)JB8Z[2H(6)?[]$SY>I_N,1,?4QZU!_#+QZSE\*O[%I9*GD6I+Z@E$C)
MY]!454NZF(F(;:F[X=_1*%;!F1.)E=/K9]&$SG`D/DOQH5$UWE?38@8&7B"S
M_I^.W;78%O#M=C7K!ZS`U;V/5E-8'IEJ,6,"<$XS7K#)1XD?`3,$,[C5\0AR
M@X0KC^,W4VXX[+L=EHP\="L7QYM%+WBN#"0H=HRX5^[.!U?:Y2QT#I!O5>LL
M#\^&8][($V*1(?F277?&O-B:CU7MV&57=K:VH6S*^K"\9@]@4^O7*([+QC"\
M8C[%'2(J/-VQWRVVC/?&,]\9QC/C1&+[AU9PZW%N:\?5RS#H2<Y+?RVY^WBB
MR8\U4=%0LDZL=1(TW#X?0+EGP*4H+2U.%V(U;'(.+;#./:UR!C07^.NYE:9!
MU`LMTF2(B_KZFRN9/^HH&&&;"`KCXGSINYBU2'R;DQ@M+B48A,Z@B?F"T9&R
M_DA)>+]F#P.AW&`E97*I(R0K#J!UA>8I(W>1G7FY8=0ER2XM=+GC7L^#E;N*
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M8=NC!TBXCIRZ\EK_`+*-C;7RHVQ!@`7V7BGLFUO7=79)3*,:RIASK+1$HWF0
M2-(W6U.I:Q:)L&/;!'8AH2/<,W?U?NG6)U&N*I^O:^1&0^ZM=RR]@Z0L$N\L
M:)Q:V8]^-E*A8BFF"71ZS>H1]Z'/*;9<^52K4#8%LDMPRQ7RK>)X3G\UY'8Y
M4',VWS+?7=5=79\8A:R3$`JL"8_8-,$#%;\;^@J_DL_+R*99U<6Q$\>+C"Z8
MCCG5.JQ'<^;(9^XWFW^HK)-_SY=/[H=$''7B,0DOP@ZW.[.F8!'\'NIIH?;B
M&-4#CUNAV\4,/&SJY307'PXF#DX>R2D9";5HT8.VT+1[S2[/G**R$)&--69A
MD4X<K$W\3/TQXF(^9!S&]Y\K([CR82,TM*A2*G4/*:0+DNQS,'`MO/-XP6VX
MN8]K@92?4?01W&P<;9>FM1[GA<5S;VK]>[2KZ596B#V)3*Y=(E"\J0K*V@+'
M&R(S*\J0A7G9;;7YD)SW[IQXK1"=,_IZ5R<>L<-PFXN!3+[V2%&8TAK]_P!-
M_)&"L.C#EP9`8BT/XPMO(H[/II_>V\):[MY<+G*/;/=L,U=KAFWGZU@Y=>3Q
MO<KHR+EH_P!SGA7O4GNHP]DD9)KF8A,_1&1$<K-7`YWDI#/S.3Y=S.0,*J,V
MLQS=&M7'Z6DG57K7:E00("QPP11'4P,=1"J>YMK\Q_B0-N:_U'I?4MCT-P2U
MK=46&S[&M:<R<=F02AR))N-CFVFF*M:-AQ5=.DQ=?:EI14RW$2$R=)6BRJ!=
MS+Q+-W*[3]"X]]*3DKI36<4W`:^U7P<W+2*K'J4QA8\-7M-V,%A\\AIH=HF1
M-RTY(2YZFT*.DRC#7?WQ]>?!"8J(A*Q$!Q,+'1<!!0X:1@(V,##B8B+`&1G*
M6`PA&A@0!&&\9[-,-,LMHQG/EQC'?QPY4W1[)3)27+DJQ8:$;#R^9<]PJ*G*
MJ;!#CE-3:3GDK-B38UL9@QF2;=R^-Z39#)*,X2XC`7;YV&@[C]+-R48?&.,V
MQNYN'7LLL,:[\A3K5W0ON&&7+]CP@)L&H5UUE\:EB,G+"69Q:*"MEVCJEI[V
M]3:J[J6%+0(5UIE*TTZ8'(5J566B1`)S)G(FT_*1\5BOA0W6G.'_`"1RTZT[
MC')IG&<M.MNXQG.GM<YQC.6U*QC/;[]L]L]OOV[>*9])EYA7Q%7/%"7V%N)E
M^<.%-H?:4XG*=]U'S84VE>5X\OY*[IQY<_97;/V\.*Z55I.2HD;;-`CZZ5KN
MY>>;BYK6$;7P*Q8LM+5%+E&'JX((#(N(4`H!1>4N.8P)[?U/*SA*<AB-8ZWK
M]DD+E!4"DPMNEE'JE+1$U.OQMBDE2A""Y)1\X%',2IF9`IMLD[));N2R&T/$
M9<=0E6"]KW,KW-'W&T@RCA?/LP:2`BZ!QGQYUS%Q,BOXVQF$_4!"8F"[@OK[
M%T>$Q&;P-2=5+U<5L#?&PI7FK22P)E<I(&D("8&)BR":!1,2/<3$^@`]>OI0
MWWF=7*7R;XSBX)Y*:0A2(HVJ!&(AIK9VO03B++%`U.5QZ*6MD4:Q.%RM,8+-
MCF9827F(MF1'EVX)MZG_``V^)<A]=5UC2/4AU7M.J;EUZA%7G=BU2HI?D)XZ
M)3[-\C9NJI@BM6RDW/S,X3-J@@YJ)EI)Q\YJ*K:'<`);W_/\_&CML<9..F^<
MC*W;HC3^W'`D.M@O[)UO4+H4"AYE0[N`C+!$'F">=E>6\^W?;[8\N4]LH1E,
M7(YUE.X_4XIS7!9OY68QS,30HWOT[;Q8LEYV*Z'DEZ;=1I]%%:R$`N>I[.%5
MQ3,TN):"MFSR'BNN&/H7P6&K3MU?S,K4E,0*7M4)K97LK'L?G3,D<3,3XR;"
M,#>X?BA>"52K12].TO=^Z+Z4SZ5?K3U.:UG`D23J6\#CS-EM)[\F&PMYW+.5
M5^IV<];K2VQP7/48<6LUU4ZAS<VW2*1U%.=(^=:SW(6\2VL]*:+.`+@W:#IV
MIT@RXQQ@T),%KE:K#2$G(/?+(F?0FWV,U^=NUC8CFI:$#<[`K4_!+A?HN7'L
M6G^*V@-=6,0CW0=DJFJ*7&6,)_+>&LK!GT1"I@'/DQY>P9K&,>9><8[N+RJP
M%NU[0M@#!AWNE5*Z"1[[I(`MMK4)91PB7V<CO$",S8)S8S[S&<L.O,I0XXUG
M+:U*1GR^&#CON3Q'A&M4N\2XC=@?,AT]#;U$V]BS3E91^!1E-,:68HW_`!-L
M6%H;8L+#X))83WZ$;'!^1\JS[%7DO(JQ?M&:%++I-K9Z+0F$Q<MR;BLWF"OY
M!4EABE1G\D0<_P`J?Z;TY1>0_38TQI'9$?\`-Z'M;AIJ:D649E3*2<Q5ATU6
M`G#8PEUHAH65CG'&92&/PTYD*4##,;QE;*<^%(]3[4YR?#@[VO.M]JZUF-X<
M+=CVC,D!8H_W4-3[66@=@2-V!0;@Z)(P]%VJB"8#B[YK:UY8#GE1S"&"%!@P
M5PR^$""%&!"1L<(*!'QXHX0((0[(@808C*!Q1!!1T-L###,-MLL#LMH99:0A
MMM"4)2G'QS<#"66*.@[%$1<]"R@ZQ)*(F8\25BY$5S'9P8^./9(",87C[*9)
M8=;5COC*?OX4^-\ZC&G=SM/'1O\`%^1NE^EAVK#*Y`\&DRO=H7E`3*=^O!>,
M/!<PT8&"&"!1K8=OB,Z0Y%RAI-R-[#3":.JA(.$TRL`=5MU6%`6*CY")E1''
MA,E,=^1"0`:_\31TS)B":EI.2WQ5Y!3`[C]=E=-24E)#.NNJ;?8R?5YF>KK^
M1&TX*>>9FLL+&<;RPMTCU!FQR<R^MSM7J25^=X1]+CC_`+GG)G;H!%4O.R):
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MU*R,.YD!B?OT,'II\*M6=(+A'.YVU=:5"V)YLO;W)C;11`\/3HZ2#BF0V(>.
ME#&!"E4RA0K#4%`+,0DR9DR):7&`&+L;<6TLSOC=7(SXC/G#`Z%T%\WHG#S4
MLIF;8/E!W$QU2J:GVHN9W;M`00@@*4V9:V/>1>J-?OOX=B1"%Q#*A?/L*QH>
MSM3-`LWDUY=6J?/?4@ZC&Z3:$0<K\]%B"635%(K,Q@CYH/&E#L%J?2`0T$0P
MT1E;3K3:TX)7C>/VKK\+I^IIU=0-C72"*NPNOZW'5JKV.RU^"=<CBK)B#APP
M'Y0"+=RX&N0<:>2+G+C.'$8RI.8>%[D#CZ>_RR_1'7YOJ&T<O8N6$Q2QK%N(
M!EI6=*"AUR%'*:0?,M590K4"C69C/?:XG6O4,?CR]1.7Q6BVM6O9RI\;6H8D
M$ULYMLG#X#882S8N`)]EK9+^OXY]<'Q6XMZ>X<:.I6@-'UQ-?H]-"RC+Y&6'
M[!:)XK"')NY7"58'&S-VVQF(]Y+RBVFT]\#@@,!Q0$<"*$GJD]/JT:YM;O.O
MB8B2KMBJ\RQ>MGUNH(=9EH*;CR&2,;=I`(;#B5);6ETC8L&VRL<D=PNR9$(%
M(LXY#'_CU6A#J%MN)2M"TJ0M"L84E258RE25)SC.%)4G.<*3G&<9QG.,XSC.
M<>*HWJL\B&R>D]SKEAYVYOF9';&Z92R;?RE/F3284DR9*)9$E$S'<3$[EW!<
M3EW'O\/V512&K"FXMVF$+LXEVL,13MT"&0E<I\1$UB0"Y/DHB'L3$3G!'JG:
M8Y&:D03N#8&N]6[@I:(N*OD=8K/!5>!LA!C)?R^WTMR4DTH)B9Q,>4X;$MNN
M%5N3:(`?]0!V)..G@BBM(Z;7V\VJ-:*[=^WFH-15V[]N_;O#9[=^V._\O;'B
M>(]56HFNI3[-6RU80!V"2U9-Z^H,@%I1!R/7E,3T11)1`^74?N/2YO0S*5+1
MU\+7N54"E^FW.O5FW9#L1>Y*[[%B\E^,.("@6M$VB"X.%C\&^=&:]Y'ZJMNG
MMGQ.92J6X#VSZV%(8E8>1'7@F)L,`<MMWY=/01[;,A%FX;<0A]KTB&2`WR1G
MDP>2'3RVWQ7WA2Z3L($ZP:DO.R:?5*QN"O".,P4U#V6W1<(H.4=2V0S3;PU'
MG.9=@I-66'C$^ZKQ4R!C*FGGO''RD3&383D=,1X,I'O.#.O`R08YX;RPRF31
M5.BE-NL.*'+'9)84MO*F"&FGVLH=;0M,+<X[3VQ6;)^&TGJ%6!&"[""\I4X)
MF(8J9[F([$@*9D2ZDQ->]R?:?!]QE5;%HIS]O/\`$:FHI0M^2M#)85"^B27^
M53(B,EQ\BVUF,-B6>#'I>EM8=@<?-+@;BU+I77FPZS(RVQHF*L-HO&WPKVR8
M'IZRWB,!1&0@FOJHJ*>E29@DHEYR4/PRVVT-A+N4Y?R*CZ_S_A$OJGUNW^1;
MY?Y_-GMV^G?2[>;'W[?IV_Z_IX9PN'0)F+7;[;:L<O%`_5%LL]GP%G2F"LA8
ML<](S?LLE9V>SDG(GO\`V^2<LLY(RWE[+365^FG2/[6DD?Q6_%']FM_"?I_Y
M!\M_`)/?R>T]IZ_O?Q<[]^W[KTO;?S>I^OC7_#.1^TW$LRYFYNFO.JV,NZB*
MR\[=:,6KL(EL014FS$&:YF?WPN)[F)CN?)9N<0Y"E&10Q^.HI9^7LUKB:M1^
M75KH0MUE[26D+*Q\B;8-A1`^9F93U/?JL41LSCWO&'T5IW=6M]AV.1K-\G8"
MO6JC[A"HS+0FZ+O56SOF4$7KRTJD78@@,5P9;<J%@AO#K.<,Y=2XC7'&3IU;
M5Y5;SN-.I84I6M+479EOJMKW#-"*=C(R&J]ME8?,;7W'66A;A?"(X!I+<8#C
M(`!CR3[&_&@Y2T25.G]`J9JEOJ-J_9>J.^EK96+1['&E?:Y,^G)^.G/9I)QL
M][(V2_8>VP3Z+V1\N^MAIW*/(IB^,BHR%#;CHB/!BP&5D+9!CA!P0V5%$O%D
M9:%%;:8;R^2^\0\I#:<O/NN/.94ZXM6<]^Z?'N![VQFZG'7"TW,O6=\U(T$,
MO/.:D5!8=X5?&L1!\3%9?7C/CVN8$O7AH^S5'FNM1U.3T0S9I/\`EOC4"G%W
MD*QKU:]6M<OU6DQ=>JNI"S*8*P:6>"&H/MPZYTEI;7O'O6-3U'JZ$3!4ZGQ^
M`H]A;N2CSB'7%DR4U-'J2EV3G9H]U^2F)%U*5%&D.J0AEA++#6UO$\3P!6L%
M`"E@*UK$06`1`B`#$"(B,?4",1$1$?41'4>KZK5J].NBI40JM5JI77K5T`*D
MH0D(6I*EA$"M:P$0`!B!$8B(B(CU/$\3Q/'?U[^IXGB>)XYZYZGB>)XGCGKG
MJ>)XGB>.>N>M,\A8K84UIG8,;JVV0-(NS]?)5%V2RU==RA@A1\I(FV"J\W*P
MJC%R<&U(Q8CWS!K$>68Q(*:+2+D-\4O2_B+^!TP):0G[17I2@RVN]M.:OJ<5
M5LPLO2@@R]ECV@:PSZ9,AJV/S<]WE(\AJ+A\1(>?EZDF*_A/@V$K',3$7(Q)
M*W6QI,`R/(6PI"'T,&C.BNJ94XVZA+J6W5*;4MMQ.%X3E2%IQE.:)\5.&-RX
MV:&O?':4WN1LO7\E&V"%U>T;KR&K)^MXJSLV54VT:9&S!;]Q?/E+`F5<=->C
MVQG1718]D,0O#0X>U4:>I5M`MIK'/T*ID+X%:V..JQ/FDFAYBR%N&2!9S\@I
M)D1"UFNO]S"NV>:8VU7KW7U5<6Y1CO:G1A-6K;NNQ[%";-%MU`N59"K=41HJ
MVI_+#/;;``J5K%8-NA]Q\V.,W3?X\\EZQL;62M(U.<J]3'T69K9LV8L5`FMC
M2]?D+1-[')G$2HMAE+$:3@&*@@08^/AOEQJB""FCA"B2<_N;-PTSM;2.@-?W
MZIZ5*V97IK85YW==*'.;.:HE*B"\@1H%<H,"R4J>LMCDQS@TK/0J,CT,,Y?<
M&07DX7,YCITJE>GU3."OXN>@JI9JW^4WZ)PY[_Z;V(N^9_Q1^J$8&]YA?RO_
M`.0O^AV]Y^^]_;8VYR5X@26YKQJ#=&K]NR^B]]:6'F8:L;!!K$9=H>5J-E':
M'L%4M-,F30`I:.*RWD@-Q!XS@C[Y.7<%86QD42G/UZU#\=!OB8I8D2)V888N
M4;!U4UBFRKX>ZXI$(6^LGO\`T&K.29"-0XOSW'XQ.3G6-42'CGMR$I=L#:L+
MOT[%I7-<_(:6M2_3^\U5%*5U=+)I%_3FWZCB.TJO'!+F7L[=@?)"AWZ9K^Q9
MG2`@LW2M[5.A6.@U+:M6GXV=(CBR*C8Q`EP]B@9&'4#,@`^8-WS92G"/026?
MP/34VYSJY0UJG<A=S;`U9'Z5D@+A70:!6]=9B[3=):*D'8YB^$SRS3&80(":
M8.B!8:.=PQ*!@*-(;9?4E1-O-!<8[SJ^.V_)[4Y"7O?&R=S$*5.V6Q"_3]-K
M$>/%F1<7#Z^UD#+'P-0CV$FN$2>(TE#LP^T-ZZFD"M=\HX=\=/V*''37F@\V
M[ZZS0V[`W]4_),5WYI\]M4S9N_R?YG,X$]K\WP'_`.Y$9>]O[CNWEWTFYU2I
MHRW.FVZU"D)OFZ(?`239MUBH*LPM[I=X5H:,S+7P7C,.<PCF6,N'A\M.WQ`M
MN_M#3S,_DK]$(TPKF^\>WELXU2V%U-30/0_'R/S0.2O:2V2D@OWK3'F=D-/(
M_J!<C:',\A;/%\J^/E2FM56N2%U_Q>H>KCM_$V&M5TW#*T;8V]!-M@:YM$LP
MAY<W'/G!BU]U@@11,<XEA]R\7-OEYN74_#'1F_=0#5:,V!M*W:&$>B)Z+78(
M+V^T*\1+FP+>'R@"&FW)!08#4MAQ!8POJ/);]97=.IC>E/M,*A;EX_TCF`=4
M>,NV[';;D7KY&FJI)7/$O:3DR.8*:V.Y,#2LI4V2A(MN1:&'CY26C17HY!$:
MDLA]W#>H_J2S4?IZ\8=(W^^8N\]!;_XYZXE;U!P0]/68#[JP5V/,BHALF3:C
M2X:#>!$#)=(*=)+C6Y0O&7R7FL"C_6JU38=8_+3$T#-)S9!D+MBYLE\)1;>0
MQ*V+A9KKTTR*YB:RB&/-'L3[BY&)SV_J_K=`#XPY]"RS8KV1J[B=*X3)SW!N
MZ;$"RE:JC5?5R\&F:ZI0S(J.4'Y&X_QCYG<7.1O&6C\DMH:UWGK3E'8Y37"R
MZ?K%&NI;5NS4QJ92(`BGQI8U5FJQ1#S<<R=,M)D7PF3#"&@"QV<&:HY1\^MC
ML\I]DZ"H6_-<<7JAI2OP*9>\6_3MJW7-[)V'984>?;KH<3!@EA5>IP09@0\M
M*/X:EW'U$OQ_S%M38P5G:-P3VK*;SU;N+DYRDF.0H7'UR:=TG4_PYK^OV(^:
MD1&HQFYWH^#D2L6NV#`MXPZ4R%&M%R(H,DI333;\<_DNUN%.QC=^6[D5QIY)
MRG':[[0J4-5-L1Q.MJYM*K7+-7&P#5[&Q#STE$XA+-$@82'B0:=,;>:;2M+#
M*GY),A,.OKE68*8N*5.@LQ0ZT+KT4HJ0+`BP-],]%>_S8#]16R$P40?C,5I/
MV<KGS,BTO/'D%2D?*JMA.9?VTW^31QT,,$VTCJIY/0+XV\CB+RT1RNO8BA#0
MA\),<LZM2G4'W;,=+/9_*B.B*_3]YZRL+=%.))K$F12YN5CK[5()RVP5;L:@
M)/,#9ZS81Y`$8Y:%AG$$(94MH9E/BPNXN3NV*9L3IL5R"/@6HODU:B8K:R"H
M!DI\X-K6D':$)@7U%(S`N?-3R5Y<:25G(ZD,=O*CS9V$1P;AIKAI<^(UVVWL
MW8"]@1<OFU;;N4N]8;D=:I:9%L29X<67+-#`BHJ7`CTQ%4&(1'!1`B8Y!'K/
M/G.:&K?3JW4]M+B]LC;O,:1VH-Q8EVG:54OP<K]0B7X%FO-0/MR"8BTOF/6@
MQH<)$C:Y3,JZ0!'""-Q[3SAII78E;817'_B'2=3(6U@NKKA+Z]^67S=$O'LG
M5"@#E`NAO@03/CU,^SJ/N/7C,5'ZIHG:P^"U;EM&CEU5Y^EE\F.WR>Q=4S33
M).OX;EU7,S%71N2AJ2/X_B(]'<EZOO61ZN'%E=3V;1X(B4U7LZ0UT_*ZT7-K
MI])B@0,;+K,VK%F$59I:Z.,RJX"?97#MU5!X[;L7,Y"RLNVM]V/*`]431.K6
MJUKLB,GN+6RK2]:SZ+#&;+CRXZV$",Q,+L%U.9Z'K!2$I>DJ\(O`!Y7F)>3E
MQ7VSCD-P_M6V=^Z(Y&ZTW:9I^_:6C+)6',.42$OD59J?;C`7;#$^SEY".1$'
MG1[4A%XE<8D<C-R#98@PYH#+SF:V;B^JQ<R=;<M/K;(>-?:9MVH_H3$!A[,K
MFTS;LQB?Q8_F[60L@8=P/B.Q"D^X\OJY-9[^GCU&C;6V[*UMB';E&X)E8$P9
M4$:D6)`3<1!*Y6X3"061+A0*^0``0F)XYO5+W(BJU;T#H>Y'&]\++--+ZUG"
M!6*.F2$OOL;7.J52\JP@JU9C:T4D4XLI0E:*1QFY><?+:[\HI?C#L[66G=><
M>MBS^GZ#7++K,.^2NX[W2QF2)Y^SV:6F`QZ?`29KK8$8_"B/D!CF#J.:P\.2
M4O;W*??O,/4W!F!VK#ZHC8'D2\_3HO:,'6XY_;L7J\`\PL.Y7F#AH(EWZJ!B
M6QA)``%TDL:.'ET*F'2FHLMU?!7GIX;+:N^_ICCQRSLNA*+R<D2;!MJ@HUK7
MKSVM,P,\!:+#0[)(34/(TLRQ`D/I*6(R22P0\I;)GHL1C,9O"[<*P9+BWKWC
M;J[<>U=.%ZG553Z%M&L6*0=MJ)VL9*6LVWI;/CL6Z*L3\A(DV.ODF!QQ;Y+:
MA\#H"&:QT77U)3?$XNC9-%H1?^<DDM<3SFN5%$F7XTBCH8DIIB,R(F+#[L+\
M:V7S::/)E.'D:=>SE[2EZ,<DSFT+N@[3>>4[C>:RP[](E&;(+`VLP%KDEHL*
MLV(_5:@W=/\`/K>ALC<&JUR\X1<AJLPW678V6W5F8X@[&J\B4)(YFX.8UZ7%
MN,%L>X:8]H<-)2>6U#DX>?9P0T.W/&V;YT?6^0MVDMC\K>2=BV=='8F&@8F1
MUQJR@Z:#$C(MV4(>5,`1^+*BP2AI$EC.9,AP8A@<9H7'JCI';%GB`"N4`/B"
M9D((_&6Z0`R1DRF/(61I&/U,=05ZS,#U'G']`J]>E[T(7*JU%AUP:_X"O\L2
<BV2BL,)<N38_Q8]7[9CP4WD6J0+@1FQ'^BO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g1023782.jpg
<DESCRIPTION>G1023782.JPG
<TEXT>
begin 644 g1023782.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!`35),3%]'4D%02$E#4SI;059!3E1?
M24U-54Y/5$A%4D%0155424-374-!3E1/4E]&4$]?-$-?3$]'3RY%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MP``1"``Z`*L#`2(``A$!`Q$!_\0`'P```0,%`0$!``````````````@)"@$%
M!@<+`@,$_\0`-A```00#``$"!`4#`P('````!0,$!@<!`@@)`!$*$B$Q$Q05
M%D$B87$C48$R4AE"<I&AHK'_Q``<`0`!!0$!`0```````````````0($!08#
M!PC_Q``S$0`!`P,#`P$'`@8#```````!`@,$!1$A``82$S%!40<4%2(R87&!
MD18C,T*A\%*Q\?_:``P#`0`"$0,1`#\`E&>7/ROU5XL**'3>0!\6'<ME.28&
MD:@0):BMY07%-D%S4DE!35)PY!U[$DWK'>0E6K-T0=OR`J/B6^SXIJX9P9M?
M*/Y_O(;*9Q*N?)MTR2"Q/90F5A''%;KQ^%UZ/7UV68B5WT>`E)`_6W;8VV8M
M9/*CTD+Z:;.D4%<9UUU_!\3->LEM;RQW)#C3]RI&>=X=6%40L:JLINS8L7$*
M#V?+'B"&,:)I.SLDF;G\\KKIMLX2%C$]U=]6B.$YT_A%H",\Y>+KD"."1(H.
M2F=11ZZYZ]9*:YVD$YME@E-S$A*//N\>89$18I)17;.K$6)9#4,ZMFFFN/=6
M8E%]G>R:)7Y5#I]=W!N52%M"II0[&B1G6O>4(;;<;=XA$<,A0:0'''7U*6YT
MVDMZP"GIVXJ[/@-3WX%/I=DJ,8%+C[B%I;7=6`?GYVY'Y0D$))-S#C\8_P`1
MSV]2G0\"KCLVQSO0-!2R7B8#.'%B`1+2VJJ<GC",<UEP25,A@(J23BIE=)Q+
MXG-$26SD4U)(#780HWTVVEG>=SR6J^.;BLN?KR0H#ND+M<N:UH#9)N.(N`1C
M=HF_E%I[CBS4@,?BJ\`;:OFZ3YF\8/Y.7C`YT@HV>.,:(EF/%7PS'2-^2.8&
M+2YMFUWW?:;XZ3&Q_M&0M7,KLJ82#=T\9BXF`LIL*2<%3RBVWZ,)'(MMEMU]
M$V^-=E,9BI^4+IN9^9+REQRL*0>X6KM&;@>3>5FS[=-B,;QK,@T%'K+(JN<H
M:(-90>1*3=X[(;:+H0\.`9K;IX99T]28])VSO7=5,J<2@2:#3:5!-2W0S)AM
MPH$E3!;7#1':;<6A2'G$NB0KIM!Z/'4I8+BR1R<EU:ATJ5%?J#4^1*D)BTAU
MIXO2&PX+.EXE">/224J392P@K'$!*1?<W#GQ`'DQ)=F<N@[\ZYDTTI.07Q6,
M3M*+DJ^IUBR*PJ7REC%BZ2[^/UX(,M]F^AA)^DY'$F:J;AGIINIEOE5-24E\
M2KY!>@>$.7Z)<<QV81J>UK9O1<,I,1@.)2!UI!H5!SQN3"OTZ9`Y"+UT)%GL
M;3W>)CL.D<)X12<H_F/92#YY<><X3PIY%K0IVEOP]8)58J@I#!'C1XFZ5>[-
MZFKT[DQN[247UW*&9.-)FB:N%5LZEG[KW4W]L>[M/Q3/43/H:P_'N'!N4,B7
M7'[+H11BT<9719$NCWX-VRT<9T]TU<(A(0GEJIC7Y_PW3CWQ\JF?;1U':U"K
M&ZO9[4Z=1H,>C52GSILN&F$PPPZAF*F7%$F,RE+2W%E]+2U$$73Q)(%M5L:L
M3X5(W'%ES7W9T*0U'8?+Y4M"EJ+2U-.+*B`G@IP#N4D8![*H\!/G=ZNNOMEI
MS+W#=[ZUXW?<><`JA.'(O7T76AMNQY)V?'A]EX3%8WET/L6/M2X9!!_A[NC)
M1X+5I^!J0<XW^7Q!?F.[KY9\A;VA^5NCRE25[!*8K!W)0(&)5I(M7L[F&)#*
M2K\F]F,0DA-N\0C;B+HILD'+5MHVW35RUPLKNJI&20Y$ZZJ%SR;<=20Z=2Z4
MW'6$9ZHIHE4T2DLKD$0WCUF2&-`ECK8./=*A28N3PMH6:NGF&XLR,*,]6+AR
MIAZBGN_R/#NLNM^RY]T?;',%XTLOT`?J:.X3G=5S@+'PQY6#5Y5R[9H==@\!
MOR&DE9OW0G54DFZW&+LOS">CO99#6T3L[:1WFU7&6Z$[1G:+/9D4TI@F(U5H
M4QB.E:8-B!RC!]+@0SR3(C**OZB4N0_C5:^"*IKJIZ*E[Y'4W)!>ZZH;R"X2
MEX?4$K``)5QX*4;@MDI7UT!YC/-=#G%,A89T+>BBF.9J+E<[/"N?X!(!LFGM
MD19S:9LVB39TP0%Z:,H_-8M'-T1JR(YOK&\[[I:/5'RJR2FOQ`?F7?O&H]AV
MG.G[YZNBU9,&%4T@]?/73E7"#9HT9M*K7=.G:ZV^B*+5NBHX66VU222V5VUU
M]=&_JV3B.+?&=>1Q@X2&L^=N/)8&C:R>%6HY`A"JJ5B45323WV333;;F4AFB
M6OS:[8U4QMC;YL>^.;3X'*E=67Y;.(8P_&**H16Q'EG&$7;1??";:K:[DLY9
M$5]5]--]$%#8X*Y;NU-<I;KN&JVF^_XJ>^U#L^H[=K5`W)5I.R]OM1MNL/.-
MN^[1%N3ULL/R7.H5PD!FX2R``%!"7;)39"4ZL:['J46HTJ*U6ZGU:FXA#B$N
MN-ML!1::26TMJR2KGRY$YLI2@"25H\S?$'^3*D+\A$X[5N2^+#I4`/FQ8G3C
MFHJQK=];)]E%23.(Q/$D(5;&WP8!F8$`CR32`2Y76##6F^<,WZZZ(]T\]P3V
M;YK?,`?G-X@K[JWQZ\2UV8)#C,QA-.1*PCA<@$8_J)F-1`K;#4XI)GD:%+ME
MYM.#&(Y%0BZJ23*.OB.'`]DP3\2AT9+;L\J-V1`N0>KPWFD1$:=@89TY5W8B
M]&T4$36;%6S3V312?RB5R)SE\Z_#W<.F8L0V5<JM6;71*?SXA*<C-%>,KB."
M1=NT0:+\]5U.23E!MJVW)2NT1#:QI,6>8QC.Z[T@>E+I5997.RF^=$T]?]%-
M+32HWN:/2=JT3<C&UZ)`K>X8[#;;0B,OPZ9&+;LQ;S,5UEN*_,6T\PV7WX[G
M`@6!#*;3*'[W-JT^EKJD]^GTU9)6MYQN1)>46V^"WVUI=2PA:5*2EM2+W`N0
MKD="TCY>O&A!&S"KYIY7ZMOJ9_J28O6=V$0K^*JNW6V,(X;K'*YKZ"UMNSV<
M?-LF2W^5'3&V--GZFN/FRC3S/._,>QDL@O#Q>]2`S]4UA!(^+MSF2J0%5RZZ
MXF?2U)R-_8F@N41F8$)3H?CY@$MI%1[H.?1#,&A(''Y!H]7<>H'WDL_9A_R'
M=O,:;:C](0=ZENP7"1P!%N@%7R]G)03HF$;-M=6R0][(]W>[%%OHFCIA;7\/
M37'RZ^LVL[L_I"D^_+5Z)I*U)C5%MQR;C(:M((^1^1<NWJN-1>MLQJ;"E<N0
M4YCV5(7^5)`Y&T*B27R[*ZI:[[)KZ6D#V4HC2J;5Z5)C2W9%,<J#]-W%3H4J
M`MQ[W-QN*MN,AH1DN(?="7VHX5'<:'31Q)1J+(W<'&94.6VY';9E)BM2:?(>
M1("6RH%X*<4HN*20@J:*R7$\^:C@Z7V6\K'Q'$>K!"[S]E=9!:87$L#Z-LEN
M3X*PK?<(35U2&F<S)U1R8/42^6VT1;/E7NC1;??"7XN%-L>STO@(\\?9'7/6
M@7COK->(VPUGT)F\CA5L"HJ&@<VC1VN@7[B>#)0/C#=A%Y.`.!FSY)%VW"B3
M(HSHV45=OQSG=NUTI?GF5Z1\FGBJN.M:8;0NL^H*_KH\Y[5H7,-?NS]N\NJM
MTF$YN/F%T;(YV8"HRWVPZM^'KA#LEB8`H2?!##=JP&%BF6?"3<;T,:(VOVVK
M:0N=WC!&BU/#:E'AC(M2DA4V03(OY>=(ED$&\H+V('$Y$1LG'-G$>$!&4D&K
MNW1]V^;"HU<;HSFR=SR:[M&AT6J0I2J?`;HT<+E,2'>'N,EZ0U':+<=WF5]=
M+GNTAFS7RO.(:7V@JF"O4I$"KU";"?C*DR#.</2<;18.M-H)/)U!*>2"GD@B
MX44I)U.;T]_EQ[X]L^WV]_?_`!]?\>O7JF/MC_'JOKYS'87]!KTG1Z/1Z\YV
MUQG&,[:XSGZ8QG.,9SGZY]L8SGZ_3&<_\9]+HUZ]'JGOC./?WQ[?[_QZKC.,
M_7'UQ]?_`(^GHT:@=_$F>&GI"<=)F.].7:SDMT1:RXK'4+TA<&8Y/3J$S2!1
M]G&64T81!KG):20Z3P\4';D_V\V*%`1T*[7>#MAA9!PU9IKWR+^:@-S8P\?E
M=JWHG7S>+*U:(CP'FV0KW8'@I#=TS_8@J<ZPO,R%"=6R[H$S<J?@EQH?YA#(
MTR:MT\(=5C.FNV,8SKCZ>WM_&<>WVSKG'UQG'\9QG&<?QZ/DQ_?^,>_S9QGV
MQ[^V,[8S\V<?7.?;.<_?/^_KU.E>TYV+1Z=2*QMVE;A;I!;-,>GJ4%QN@`F,
M5(+3R%J80.DE:>FHMI0%'DDJ5DY>U6W9TF="J,NFJFI*9:(P20]R'SY4?EYJ
MLH@"P/*P^:XY56_BD[7XWY]:=!3WGZX4.@K<V/5OSU3,'KF23V<U7&'@51E9
MM_VOM!AAQI7)9C%R68/2\5=$=)4O*94_FI5N-2B*#)WLWQR_#K]>=W0>>6'(
MC2W)`N$2QC#(\PNZI[%'2*;NOT5,H8(Q\*HK&"C("`T=#16Q55%PV)D5WK5H
MI\HQQMOU"/DU]O;&,ZX_VUSG3'_USCT8UUQ_'O\`WVSG;/\`[[9SGV_M[^WJ
M:][9]R+B2D,QH<>HR9+;GQ!(+R6(S2D!N&Q#DH>:#:&TJ3S<4XXI3CBU$J7<
M1T;(I@>9+CCSL9EHH$8DHZCRLKD./(4%J6H_VI"4BPQ<7/)_\AGA,Z^X4N.,
MU@+B\^ZH&R:OADZ3L6E*5L\S&V*ZYPX$>Q$E^4:2A1J9%)BF1#;5P_1V78%V
MNZ+5/Y-MM\9+5'T+>LD`S.^N9>@)(MROR?S_`%+&N?4JXLP38]R*05L8@4%:
M[!6`!.9`*4U+CSI&T+`$-4-VS4<G!H\79328#78SK2[Z^^,Y_JSG&,^V,;[Z
M^^?XQ_3G'W_QG/IM'D,2-/=E^3.T#JVV;&9772E$M!+MUEV3B],5MSC7<Y@#
M=BFIMER-`S:76S9$[TT132:DB)1RMLHZ59:[(=4^VBK*B1&9E)ARIT=M;2JD
MA]Z*\XETI$GBW';2TP7V4AI1:"2C^JV4N`$,3L:&A^0ZS,>;CNE"S%6TAU`4
M@W:NXI:7%!MPE8%\VXJOA09A[L\-T`EWA59[472`.M^N*YJ"ONCC"-=`WT4D
MEAST'!&INT:F+H+DEC;F*:CB<F:5S6[Y^[#P0P$C@R+CQGX&^BD:'EB@[B@O
M;,&APBP^BHIXXI2^B#OHF\P=@V5'^993STZIX5)>@%Y%<@Y0159B'?G]IO7Z
M$@W(?F?S[;0&(=:R9-MIM*U\Y_DP35`2'QC<CV#$AO1%V@58[TE>Q.5L0U6<
M,<]'5=A\^G=OSA-XD-BLSD$<U)@HS%7!!I)\MR>5AK564EX6'-QHNA.W6G7D
ML@_$O',;'V+X<?$11HBS[J936:G:.A75(^B1XYNA+KG)K`2\O<1";VSN)!PR
MHQ4>(2V:DBYHTU;BRY(88A.7H_M"J=*IE4HYB1)L2HFHK0B0`?='ZBEN[R.3
M:@LM.)6ZT@J2GJ.*4;WNFXE[<C3),.7U7&78_002WR`?;8/T+`<2A/(625<2
M4IO8$8TLV<4+8](0-3O/@+_Q'NCN,XW8L+"\[<N=93FQ[DI3J)Q,49$'VGK+
MFP..:6LMR=7H!KI*H-)[8>L"UAR5I%5F\7S$\_N=[L7X<NA>L+,\HO2W9W7M
M7W!%)8I3<S+[RRRZPDU<#S-@6[,HT)4&QME(`XIHD,"PR.$!XL,#PHVCH-H.
M'[:(H;H[+.M<T]75?XLO%K7'?_2.E_\`05F^0>:P"_;#$U##'$I+H65?<#:%
MHA5M:P5P?'1BM*?J.OXT.@D1&+'&K3\`,U:COSCLH-%,U>>2_P`TM*>.[F:&
M6U**[M\A:EZ59I)Z#JHO6$Q;IO+!D$>9D(G75J21FU<QV!21-\2QB1158RZD
MVK4#($F+!QLDS6<5=,W2*5MVL4)BF13(K""P_5RX[[VB(2PKW1I`_D]*[5U8
M!65@K^A-I<NE&74H4Y<MT-PE%;<3@GHJ=LI)=4K"P1S-NZ1FPSJ(/\2UP)85
M9=V6QU5!6"<\J&[&L9F,Y6BKIO)"M.6`SC@>+GQ-HQ\3NZ/1&.RA(4)DD4EA
M@8VC9!0NN#W*(E46C5ZGZI?B0?(-4O&\<XR@)"H6ZD3A>E8P>]51<@*WG%H4
MV;;#`@T)C$B5B+N0QX4IJ(CLJ<QER2'MFS%91FZ+-$B/J6-\.?SLJC3M_P#7
MW1T,N-_WEUG8A$[U1.;_`*1E%3ND-76WZD'J"LQTX8,G1VM8FR68KEBX-@A%
M21QTS`LMW3"&BFXU_4+SASS&CB4IC]%TP!DB2OYA&1!:M@@HXFOGYL873+L0
M*!#5;Y=]]?Q-'&-\XWV_J_JS[[.G>TZ$Y0J91MS;8C;@%&+?P]]R0&19A`;9
M+S:H[OS):`:60HMO(`+C)6.1HI.U'D3Y<VEU1ZG&<DA]M+8792SR44'DFPY?
M,`1=![+(O?GJ>&_PN7S+I1OY`>KZOF$)HCG048OJ`UW.HV63L#I2P8.()3.'
MLVT(?L7$G_824F&CS!PD7%)EIR3PRC\:9O4R!$NU;,X<XJZ;OCO7E\79?/=^
MB@MA=/5O)+&D<MIFS00EB$<3MK/)P1-GY#%60EKKJU:%-G#@@\32<+;:I?/^
M(XTUVZXN/P_?.,>WOM[^^?K\V<ZX]O?;;_J]]<?3&<Y]\8^F/ICT?Z>,^WS9
M]\8]_;*F^?IGZ>^<9VSCY?K]\X]O?_'IP]L5;5(K,AV!#6:G%1"C(2X\ANF1
MFVY*4ICI%^JXIV2I]QQRP6M#:$H0VA*`?P73PU!;2_(28;YD+5_+)E/%3:BI
MZZ>0^CB`A0LE1\DDQD?B2)E>]15GQ59O*-4R*67C">J'\S$R:%5=(9\3#QD3
M6DI1DT.E*41"$GF];6HD;0A\]C9?.H:7!%E6#U%SNW2RC;OAS.<!M,G.[[*C
M5<SJKJ[Z%DG/5GU7!YS$91$7L$A\@A<S/':ORWE`<2[<.JALXU.*Q_HU6W5`
M1B,FU-\MCK)=S*`V^3WUUSGY<[9S\N,;9USMG'WQ_3G'O[>V?I_'U]5U^3./
M?&<;8QGV]_FSM[9QG[>^<Y^OO]_Y^WO]L>L1_$SHVR=MHB-H2XHB1.#KA>D,
MB<S/9:=:(Z9]V?:7T%WY-ID2``.JH&\^%-_$Q4NJLJ2!P8*4]-M985'6M!^L
M%QLMA:0>)Z23:^1Z]'KSG?7'WVQ]_E^__F_[??\`[OI]OO\`V]&=M<8SG/T]
MO;^,^^<YS[8QC'WSG.?IC&/OGZ>LP,`:M=898]BPFI()+;,LF4@X3`8)'BTK
MF,ODK]$8!C<<!LU'Y8R6?.-M$V[)BT2W55V]\[[YQJDCHHLHFGO%YU\@W:_<
M_1?%DUYEG<AHFDKXZ=;/N=Z29QB-JRJZN&:0*:NNI^S>K%Y4(+F(I5<S9J#Z
MOYQKB,JPHFM*I@,DYL\<)IC!Z2`/+QY*77E&[UA'B$Y78V-</-L"E[@IU6%H
M)?&9+U?-H`_9D=:&`3G;32.P"I8S(AZ8J>6Y*BS*#AB?ZS,E/US>!14)+Y,/
M*G-$3X;KJT>N.IY!7C&YW54#DK4F,9;O6-.<U\UTN$7?0/F2@FQ1%!^'HNF`
M31RY5)N6C63VY/'!BPY2BF_+`P()IS^#]N^1;QWOZX^QS9P%A<C/8#!SC!&?
MU\^+CSB'FL\JD:\5'(9.TV#4'*^@K&(9@/-M7FM7CI&83USEOL]-&!@MRS+N
MX=`QCG0U),,'314B[6!QAL19DI$S6USSD/;RAV=S53UC=.3[G6GKRG,21E4Z
MJV-T+*RH^!J'7KTC'XRZ>D+ERYWD(R*.`2$M0SLH@RE>#3)FJJS;H*;1P_'!
M7<V^(&\HTK\MW0\3>#.&>19)O7/$U/2YFX=#I5+8ROH7"2`@SRXU&NW$6(KM
M+0L)?7#X>]L0I%(6DH0#1%ZBG.$T3QIKC7Z;9Q[YSMG&,9VVVSG;;.?;^<YS
MG.<_?.<^^<YS]?1:_DC]QZ8[_G]_MHO;T/Y'^]_^LBQ)`^GH]'H].TW1Z/1Z
M/1HU@]C6975/P\Q85KSR'5I`H]HW5/36?28-$(H%2=ND6+10K(#[U@*8:NGK
MANS;9<ND_P`=TNBW2QNJIKKEO_M#F+CN01JQ.T;.FUM4VUB=+O3-L7'S5?MH
M4B6L*F($()RT>/F;NHY2%;6:V#CG9+:!+O4G\A::F-@\5+MVA7\HK7RT^.@)
MY/\`DUQSB7EF8DX$V5`K:`[O_P!>4B,E,P%V^4_9$_;1<P!DF\,EPLF4"$W\
M=*-)#''#IE)@6RQ(0@V721<U*>2.TN54.&8QQWQA6L$%@*QAX&=)=HVO*:S$
MPRH9'$9#%HHY@I'F=*SY,`)MH4)BDL$%CS1U(8L]-LW$D;O'V'R;23G%Q;]^
MV/QZBWCSVT]([$$#.;D#'X.3^E_T(S&Q[X1H3Q<\3AK>?U/&Z^[:Z^T/F>&>
M2!>SN0L./H%+TD6NW3MW+2A](91>7;+.)EL)/+TLTA*2D.ML^G!Z59QL'"9"
M4)[0X9\+U7<=>+&7WSY6[IE-04M=BL(OSJ3GB*AL`;2LIC!R+\ISWSY.;!W)
M/945:EBA7:9D:7@@"-3"26C(0[([,F^L.T0://57X197$+^FWDT[#F@[R6>1
M-'9F<J*!RLAM1G+=4$F9#V!QNM1A,=9Q`2/@C!X\5A9N3""C86\;ZFDHKB:O
MU9;K</([XS.X>UN5KTD,PL*O)AU9*`,>B%$4=#B[^,<_<Y0,S,@:%U[US,9F
MPT(SOHBRJL3.Q5S?UE1P&F$%DR$-KZ*U^!-2!Y($`[``^";X%\>;7Q:YL,_X
MTH/8E0[V\'T!%O&/(P/!)O9K/QF^2/I7HRRKM\FEXVI,>2/$-S6X8T;ROQI6
MS0#A"XI\'!MP%;4[&@;<;N:L"1@XNJB2D@X`3'"24X>!1S%X*@L)DRXU.G.5
M^69Y3^N95YD>SH-(3O*7&UHMZ4\:?%$6U;&]KXZSEI35*MH+#OS6R@.<S,:[
M3#S6T+`;ZN!K<PS$F/QV=<5F6:M'5KF\(?19CQNS*M*W<UX"Z*CM*@J)Y3H*
M,3%\RHWEZH9)+(YO?V(K.CH@;FQ.LN@8*E+!]O=.2V+@/U7>1D8'!Q,*@[TN
MZD6UJE\7_;]$U]1"%,B^9(G9L+JZ5TM1[>2R67GJ9\:%?G(OJUD=CUE#A<;8
M%^K^R+N./GQ:WKVDSVL1:+M':,1<<VKUT8&28SX!%[`8O;MW\''DY&18:,?\
M@<YR<=NWV&<W[A-LC+>E$=1>7OH+RYWOS+&/)95^M?U?4A^4]KNXGS]&75`<
M4OF^60]>LJ,D$_>_G;$LV#EWNXI*TI@];1G)(-*9!,X])QT;(1M/:`/R6=7>
M6KI`QR9X_+]EE$>.SDF'"L=G>4$J-C@RX;19101OJ<?US("`IG#J^=V'H!+E
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M`T#+""_Y$A>,N6B;9K(IJ2E+K=8/7K8*+D+T.',%"S#=A+R4^03M0E3G4:_0
MDPY<2D%R1&\*MYJJ>9,8_3W+WCNK24+.[:ZT\B,D2!D2DS1N$4V4KBD*^EJH
M$?9A15\;K:&%71&*AWJJ[V^&FL8KXS::H863@=O7U5ED5`;4@D?.;5+649IU
MB0*$+[@%(20X-+YS<=Q&C*<HGW0MH,-Y!.W,>CL9080ZOHI$X.R<PICQ>3^K
M*LTGAVB:`2<TH%5F?)WC2HPUL`YO&7$`&ZMJWGO4%\30<,E75USQC;5DD,L&
MP0`V"5DHW>G*]@[R7Z"Y4BF;=CFV2`<"W?U/V[]QHN/.3?UQFU[>1:V#@=S?
MU:R[9\U'6L;[1YV!P&;EZ-TVW(]+S+EF9#('%@%6\,1"$2*58-]J2B4#2AP-
MT#T<(;MI+%JM`R2*M>>XPXK^/%4I=;$Y4R.LNGQ`727`'BKYY6Z>51Z'\J/7
M*4NM2DZD*B]LNH53=H2QV_IR970$B^HDDBP<BGZ*-<P(6F.D\P8+!@FJ[%$0
M8+IK8\3?@+*0.U[*\@_E:;Q/H?O6YIS*98M%R:XZ>U+4GY\LKEH5',W.CL'*
MY<Y9(,]0#AVV<`ZTCK<0`BS'4HQ7-9MEZ>$"4UGY8*4[6XKY9YC,UI"*&4CD
M)B,VFSFLJ_I;IQ&62'<7>4^AP>-RF46Q&(U#Y#NXAL-ACD$2924,!%M2D2$A
MQI=JHQDW)^W?MDVO?.!:PMC&+Z2X.,8O:]NUQ8=QD9]0<W-CICCMWH[R_P#(
MS'F!&?\`='1$J\O7>IA[EOR#64BC[.FN;*$L,<3A44A#JE185[%EKNEDTD`Q
MQ$YHS_)/ZZ=0H]@<Z,/QCJ3/E$=M>2#I;ASEZKO"]SAT5</;GE=O<LQB_3E[
M[3@M9I*HYO:"3,47H:EY._74?-)FRU591IEOKC7>M0OZW+RZ@N:2-)"-K%KS
MP)^0QWY.NF^H[;Z7B!;>T&X5A&>Y4-6BO141B!^-,1ME@N<:1T%N(50]AOF>
MCNL8)9AJ2R).CJQW<N(&&EDV,;2(1L:M/`W?%<>1#HFS*M3KZA*:+0*(TWS-
MT7%93I++4Y\Y\S#PXZSPU.UP<$.2#;K>T3:LK:R/IZRI66UB"4JF4_"BYY.9
MHHF$3S<B_P"`?M]KVL3@][$'T"CM]5L#'VQ?]<&WD8[6MIGZ"7N8\3`RN_#I
MXAX["[W\MO0<@8!^R.JM!PB7AJYM-^UU7(U)79`DUV&$!M.,D"3B1&9.F0A=
M>M1L@E!\06FA<LVBF!]54WV5>?9]=^#ZH_(%T]U-8UF12/&_*Q:UB6D9E5%Q
M@XPE@.R)`+KZ'%-%VM<PFBXZBWV?H#73)_8LKE0.&2)!INV:1T6^5RQX2.F>
M,>X>WIMRY$:*J.,=#OQD:HWL@Y)UK)F_,?/[T*@K-8S7-#F`N2<NZ'E,I39;
MEIY/9TQA.=!"4J+*S=T2*11_A'C+\%_8]`!^DJRN<O%(`OTO:\C5ZHZ_$6PX
MM;I#I#G[>1JO6E%U0@E&0"=%A[2;*%BEVVY*)&>L8@[DSME%(D((C@,FCAZ8
M-P?2_>U\VL/.00+B^;Z/!R+>I.>.,6N#?Q:WKV\R-/&_&^8HCQ50<7XW$/!7
M-L:BKZ-U8X)"UA9"4!HW(S4??V"\RX107-*V.=%E)SI+=TM-)F@>1E#7&&15
MMKJN'U8(K%H]!XQ'89$0PV.12)`Q,9C$>#-$6`<!'0`]N*"!!+!OKHW9#!(Q
MHU8,&B&FB3=JW22TUQC7U?\`TX8`'H!KGH]'H]'I=&CT>CT>C1H]'H]'HT:/
M1Z/1Z-&CU3.?;&<_?^V/;WSG^,8]\XQ[YS],>^<8]_OG'JOKSO\`].W_`*<Y
M_P"<8^F?^/1HU$1\D?DSM_HJR+-YYH1O8PSG^%69).;(K!J6(9:=-^4/JZ-;
M["IO05/G0[[4K4'%M.$UL,^O>CAJPDGD<U*P2-RV-$R6=DW"_"+X<8QXV*[E
M-HVB*KH]VE?JJQFXY97X%L*@]:@'KE$@,H2G&VB"/Z;7D2W1::DGS1!IM+S#
M1NZ<ZJBQ`))!4O(%%4C"NMN\;$AM.57$K`,6;'&1:=1FO8B!F)1G)!"LFD30
MC)Q0AH;>M3\DVVD!INY?*I%3>VQ9]HN_SEQES_7[8_QC_P#/30;W_0_N+_X.
MGJ-OE'C_`#@?Z?\`VYC&,8]L8]L8_C'JOH]'IVF:/1Z/1Z-&CT>CT>C1H]'H
,]'HT:/1Z/1Z-&O_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
